

DISSERTATION FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PHD)

Effects of Ginger Supplementation on Functional Dyspepsia
Symptoms and Fat Loss among Patients with Functional Dyspepsia

By Lemlem Gebremariam Aregawi

UNIVERSITY OF DEBRECEN
DOCTORAL SCHOOL OF NUTRITION AND FOOD SCIENCES

DEBRECEN, 2025

DISSERTATION FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PHD)

Effects of Ginger Supplementation on Functional Dyspepsia
Symptoms and Fat Loss among Patients with Functional Dyspepsia

By Lemlem Gebremariam Aregawi

Supervisor: Zoltan Csiki, MD, PhD



UNIVERSITY OF DEBRECEN
DOCTORAL SCHOOL OF NUTRITION AND FOOD SCIENCES

DEBRECEN, 2025

TABLE OF CONTENTS

TABLE OF CONTENTS.....	3
LIST OF ABBREVIATIONS.....	6
1. INTRODUCTION	7
1.1 Background of the study	7
1.2. Epidemiology and Risk Factors of Functional Dyspepsia	8
1.2.1 Pathogenic aspects of Functional Dyspepsia.....	9
1.3. Management of functional dyspepsia.....	10
1.4 Ginger’s nutritional and Bioactive components.....	13
1.5 Ginger and Functional Dyspepsia	15
1.6 Ginger on Fat Loss and Anthropometric Parameters	16
1.7 Ginger's Mechanism of Action.....	18
1.7.1 Ginger's Mechanisms of Action in FD	18
1.7.2 Ginger's Mechanisms of Action in Fat Loss and obesity	19
1.8 Tolerability and Safety of Ginger Supplementation	21
1.9 Rationale of the Study	22
2. STUDY OBJECTIVES.....	23
3. MATERIALS AND METHODS.....	24
3.1 Study design	24
3.2 Study Participants.....	25
3.2.1 Inclusion Criteria:	25
3.2.2 Exclusion Criteria:	25
3.3 Randomization and masking	26
3.4 Procedures	27
3.4.1 Intervention.....	27
3.4.2 The Nepean Dyspepsia Index (NDI)	28
3.4.3 The IN-Body 720 Body Composition Analyzer.....	29
3.5 Outcome Measures.....	30
3.6 Ethical clearance	31
3.7 Data analysis	32

4. RESULTS	34
4.1. Socio-demographic and Baseline Characteristics of Study Subjects	34
4.2. Effects of Ginger on Functional Dyspepsia Symptoms and Quality of Life	35
4.3. Effects of Ginger on Fat Loss and Anthropometric Parameters	37
4.4. Detailed Body Composition Metrics (IN-Body 720)	39
4.5 Segmental Fat and Lean Mass Analysis.....	39
4.6. Overall Changes in Body Composition.....	40
4.7. Subgroup Comparisons	40
4.7.1. Comparison by sex	41
4.7.2. Comparison by age group.....	42
4.7.3 Comparison by BMI Category	42
4.8. Reported adverse effects and Tolerability.....	43
5. DISCUSSION.....	45
5.1 Ginger's Impact on Functional Dyspepsia Symptoms and Quality of Life.....	45
5.2 Effects of ginger on Fat Loss and anthropometric Parameters among FD patients	48
5.3. Subgroup Comparisons	49
5.3.1. Influence of Sex.....	49
5.3.2. Influence of Age	50
5.3.3 Influence of BMI	50
5.4. Clinical Implications	50
5.5. Safety and Tolerability	51
5.6 Strengths and limitations of the study	52
6. CONCLUSION AND FUTURE DIRECTIONS.....	54
7. SUMMARY.....	56
8. KEYWORDS.....	59
9. FUNDING	59
10. ACKNOWLEDGMENTS	60
11. REFERENCES	62

12.	APPENDIX.....	72
12.1	Appendix: Study Questionnaires.....	72
13.	LIST OF PUBLICATIONS	108

LIST OF ABBREVIATIONS

5-HT - 5-Hydroxytryptamine

BF% - Body Fat Percentage

BIA - Bioelectrical Impedance Analysis

BMI - Body Mass Index

COX-1 - Cyclooxygenase-1

EPS - Epigastric Pain Syndrome

FD - Functional Dyspepsia

FDA - Food and Drug Administration

GI - Gastrointestinal

IL - Interleukin

LOX - Lipoxygenase

LPS - Lipopolysaccharide

NDI - Nepean Dyspepsia Index

NDI-SF - Nepean Dyspepsia Index–Short Form

NF- κ B - Nuclear Factor kappa-light-chain-enhancer of activated B cells

NSAIDs - Non-steroidal anti-inflammatory drugs

PDS - Postprandial Distress Syndrome

PPIs - Proton Pump Inhibitors

QoL - Quality of Life

SD - Standard Deviation

TRPV- Transient Receptor Potential Vanilloid

USDA - United States Department of Agriculture

WHO - World Health Organization

WHR - Waist-Hip Ratio

1. INTRODUCTION

1.1 Background of the study

Functional dyspepsia (FD) is a common gastrointestinal (GI) disorder characterized by persistent or recurrent pain or discomfort centered in the upper abdomen without an identifiable organic cause based on the Rome IV criteria [1]. It substantially impairs quality of life, often leading to dietary restrictions, nutritional deficiencies, and psychological distress, while also placing a considerable burden on healthcare systems [2,3]. Although conventional treatments, such as proton pump inhibitors (PPIs) and prokinetics, are frequently used, they often provide only partial symptom relief and adverse effects may restrict long-term use [3,4]. This highlights the need for safer, more sustainable food-based alternatives. Nutrition plays a pivotal role in the management of FD, as dietary factors significantly influence symptom severity and digestive function. Consequently, there is growing interest in the use of dietary interventions, particularly functional foods and medicinal plants, as promising, food-based strategies for alleviating FD symptoms.

Ginger (*Zingiber officinale*) has been widely recognized for its dietary and medicinal benefits, particularly in gastrointestinal health. It contains bioactive compounds such as gingerols and shogaols, which exhibit anti-inflammatory, antioxidant, and gastroprotective properties [2]. Studies have shown that ginger can enhance gastric motility, reduce gastric emptying time, and alleviate dyspeptic symptoms by stimulating digestive enzyme secretion and reducing oxidative stress in the gastrointestinal [5,6]. These properties suggest that dietary ginger supplementation could serve as a natural and effective alternative for managing FD symptoms.

In addition to its gastrointestinal benefits, ginger has been associated with improvements in metabolic health, including weight management and fat loss. Research indicates that ginger

supplementation can enhance thermogenesis, increase lipid metabolism, and improve insulin sensitivity, contributing to fat loss [7]. Since most FD patients experience metabolic imbalances, including unintentional weight changes [7], investigating the potential dual benefits of ginger in both symptom relief and fat loss is particularly relevant. This study aims to explore whether ginger supplementation can serve as a holistic dietary intervention for FD patients, addressing both digestive discomfort and metabolic health. Existing research often focuses on either gastrointestinal benefits or weight management separately, leaving a gap in understanding how ginger might simultaneously influence both factors. By addressing this research gap, the study aims to provide scientific evidence supporting the role of ginger as a multifunctional dietary supplement for FD management.

From a public health and clinical nutrition perspective, identifying cost-effective and accessible dietary interventions is essential for improving patient outcomes. If proven effective, ginger supplementation could offer a nutritional and natural alternative to pharmacological treatments, reducing healthcare costs and improving overall well-being. As dietary approaches gain prominence in disease prevention and management, this study contributes to the growing body of research on functional nutrition and its role in gastrointestinal health.

1.2. Epidemiology and Risk Factors of Functional Dyspepsia

FD affects approximately 10-40% of the global population, with a higher incidence observed in women and individuals under the age of 50 [2]. The Rome IV criteria classify FD into two subtypes: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), both of which exhibit overlapping symptoms and are associated with multifactorial etiologies, including delayed gastric emptying, visceral hypersensitivity, psychosocial stressors, and overweight [3].

1.2.1 Pathogenic aspects of Functional Dyspepsia

Functional dyspepsia is a multifactorial gastrointestinal disorder with a complex pathogenesis involving several interrelated mechanisms. One of the most studied aspects is delayed gastric emptying, present in approximately 30–40% of FD patients, which leads to symptoms such as postprandial fullness, nausea, and bloating due to prolonged retention of food in the stomach [8]. Another key factor is impaired gastric accommodation, where the stomach fails to relax properly in response to a meal, contributing to early satiety and postprandial distress, particularly in patients with the postprandial distress syndrome (PDS) subtype [9]. Visceral hypersensitivity, characterized by heightened sensory responses to normal gastric stimuli, is also commonly observed in FD, particularly in those with epigastric pain syndrome (EPS), and is believed to result from peripheral or central sensitization [10].

Additionally, *Helicobacter pylori* infection has been implicated in a subset of FD cases. While its role is not universal, some patients show symptomatic improvement following eradication therapy, suggesting a possible pathogenic link through mucosal inflammation or altered gastric physiology [11]. Abnormal gastric motility and dysrhythmias, including disrupted slow-wave activity and coordination of peristalsis, may also impair gastric processing and contribute to dyspeptic symptoms [12].

Moreover, psychosocial factors, including anxiety, depression, and stress, have a strong association with FD, and dysregulation of the brain-gut axis is believed to mediate the influence of these psychological states on gastrointestinal function [13]. Emerging evidence also points to alterations in gut microbiota, or symbiosis, as a potential contributor to FD pathogenesis, with changes in microbial composition influencing inflammation, motility, and mucosal

integrity [14]. Overall, these mechanisms suggest that functional dyspepsia arises from an interplay of gastrointestinal dysfunction, immune responses, neuropsychological influences, and microbial factors, underscoring the need for a personalized and multidisciplinary approach to diagnosis and management like nutritional supplements.

Notably, women are more likely than men to develop FD [2] and obesity has been consistently identified as a significant risk factor [15,16]. Multiple studies have established a strong link between high body mass index and gastrointestinal symptoms, including upper abdominal pain, bloating, and diarrhea [17]. A recent large-scale study further confirmed that elevated BMI is significantly associated with increased risk of FD in females [18].

This association may be explained by the role of visceral adipose tissue, which is metabolically active and contributes to systemic inflammation by secreting inflammatory cytokines [19], [20]. Visceral fat also increases intra-abdominal pressure, potentially exacerbating FD symptoms [21]. Obesity, characterized by excessive accumulation of body fat, not only predisposes individuals to FD but also worsens its clinical manifestations and complicates management strategies. Consequently, interventions aimed at alleviating FD symptoms while concurrently addressing excess body fat may offer a more integrated and effective treatment approach [17,18].

1.3. Management of functional dyspepsia

The management of functional dyspepsia remains a significant clinical challenge, primarily due to the disorder's heterogeneous symptoms, multifactorial pathophysiology, and the absence of clear structural abnormalities. Current therapeutic strategies are aimed at symptom relief and improving patients' quality of life and can be broadly classified into pharmacological and non-pharmacological approaches [1,7]. Pharmacological treatments include proton pump

inhibitors (PPIs), prokinetics, and antidepressants. However, their efficacy is often modest, with many patients experiencing only partial symptom relief or adverse side effects. Non-pharmacological strategies, such as dietary modifications, have shown some promise but are not universally effective.

In recent years, increasing attention has been directed toward natural remedies, notably ginger (*Zingiber officinale*), for its potential gastrointestinal benefits. Traditionally used across cultures for digestive ailments, ginger contains active compounds like gingerols and shogaols that exert antiemetic, prokinetic, anti-inflammatory, and antioxidant effects. Additionally, ginger may aid in fat loss through mechanisms involving enhanced thermogenesis, improved lipid metabolism, and modulation of adipogenesis, offering a multifaceted approach to symptom management in FD.

Pharmacological therapies are the most commonly used interventions, particularly in patients presenting with moderate to severe symptoms. Proton pump inhibitors (PPIs), such as omeprazole and esomeprazole, are frequently prescribed for the epigastric pain syndrome (EPS) subtype of FD. They function by reducing gastric acid secretion and have demonstrated modest efficacy in symptom relief[4]. However, a significant proportion of patients either do not respond or experience only partial relief. Prokinetic agents like domperidone, metoclopramide, and itopride are recommended for the postprandial distress syndrome (PDS) subtype due to their ability to enhance gastric motility and accelerate gastric emptying [22]. Nevertheless, the clinical use of prokinetics is often limited by their side effect profiles, including extrapyramidal symptoms and cardiac concerns, particularly with long-term use. H₂-receptor antagonists (e.g., ranitidine) are sometimes used as alternatives to PPIs, especially in patients with mild symptoms, but their efficacy is generally inferior and they are subject to tachyphylaxis with continued use [1].

In addition to acid suppression and prokinetic therapy, low-dose tricyclic antidepressants (e.g., amitriptyline) and selective serotonin reuptake inhibitors (SSRIs) are employed in patients with overlapping psychological symptoms such as anxiety and depression. These agents may exert their effect through modulation of visceral hypersensitivity and gut-brain axis dysregulation [23]. Another important pharmacological strategy involves the eradication of *Helicobacter pylori*, which has been shown to produce symptom improvement in a subset of FD patients. However, the response is variable, and eradication does not consistently translate into long-term symptom resolution [2].

Non-pharmacological interventions are increasingly being recognized for their role in managing FD, particularly in patients who are unresponsive to or intolerant of drug therapies. Dietary modifications, such as consuming smaller, more frequent meals and avoiding high-fat, spicy, or fermentable foods, are commonly recommended, though robust evidence supporting specific dietary patterns is lacking [3]. Psychological therapies, including cognitive behavioral therapy (CBT), hypnotherapy, and relaxation techniques, have shown efficacy in improving symptoms, especially in patients with significant psychological comorbidities. These approaches may act by reducing stress and visceral hypersensitivity, which are thought to play roles in FD pathogenesis [24].

Complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and probiotics, is widely used by patients with FD. Among these, ginger (*Zingiber officinale*) has received considerable attention for its potential gastroprotective, prokinetic, antiemetic, and anti-inflammatory effects [5]. Several small-scale studies and clinical trials have reported beneficial effects of ginger in alleviating dyspeptic symptoms, though heterogeneity in formulations and study designs limits the generalizability of findings [25]. Despite growing

interest in CAM, evidence supporting their routine clinical use is still limited, necessitating further rigorous clinical trials.

Despite the availability of various treatment modalities, several limitations remain. One of the primary challenges in managing FD is the heterogeneity in symptom presentation and underlying mechanisms, resulting in varied and often unpredictable treatment responses. This necessitates a trial-and-error approach that can be frustrating for both patients and clinicians [2]. Moreover, many pharmacologic agents, particularly prokinetics and antidepressants, are associated with adverse effects that limit their long-term use and patient adherence. Symptom recurrence is also common, highlighting the chronic and relapsing nature of the disorder [1]. Importantly, most current treatments are palliative rather than curative, as they address symptoms without fully resolving the underlying causes of FD. In conclusion, while both pharmacological and non-pharmacological strategies provide varying degrees of symptom relief in FD, their limitations underscore the need for novel and well-tolerated alternatives.

1.4 Ginger's nutritional and Bioactive components

Ginger (*Zingiber officinale*), a widely used functional food and medicinal herb, has been traditionally valued for its nutritional and therapeutic benefits. Rich in bioactive compounds *Table 1* such as gingerols, shogaols, and paradols, ginger exerts potent anti-inflammatory, antioxidant, and gastroprotective effects [26].

Table 1, Bioactive components of ginger and health benefits

Bioactive component	Pharmacological/Health Uses	References
[6]-Gingerol	<ul style="list-style-type: none"> - Antioxidant - Anti-inflammatory - Anti-cancer (colon, breast) - Anti-nausea 	Mao et al. [27]; Shukla & Singh, [28].
[8]-Gingerol	<ul style="list-style-type: none"> - Antimicrobial - Anti-inflammatory - Enhances thermogenesis 	Mao et al. [29]
[10]-Gingerol	<ul style="list-style-type: none"> - Anti-tumor activity - Cardio protective 	Shukla & Singh, [28]
[6]-Shogaol	<ul style="list-style-type: none"> - Stronger antioxidant and anti-inflammatory effects than gingerols - Neuroprotective 	Chrubasik et al., [30]
Zingerone	<ul style="list-style-type: none"> - Antioxidant - Anti-diarrheal - Antimicrobial 	Ravindran & Babu, [31]
Paradol	<ul style="list-style-type: none"> - Anti-cancer - Anti-inflammatory 	Ali et al., [26]
Gingerenone A and B	<ul style="list-style-type: none"> - Anti-obesity - Improves insulin sensitivity 	Wang et al., [32]
β -Bisabolene, α -Curcumene, Camphene	<ul style="list-style-type: none"> - Contribute to ginger's essential oil - Antimicrobial - Flavor and aroma agents 	Zick et al., [33]

These properties contribute to its ability to enhance gastric motility, suppress nausea, and alleviate visceral hypersensitivity, making it a promising dietary supplement for FD management. Additionally, ginger contains essential micronutrients, including vitamin C, magnesium, potassium and other components *Table 2* which support digestive health and metabolic function [26,27].

Table 2. Nutritional composition of ginger per 100gm fresh ginger

Nutrient	Amount
Energy	80kcal
Carbohydrates	17.8g
Protein	1.8g
Fat	0.8g
Dietary fiber	2.0g
Vitamin C	5mg
Vitamin B6	0.16 mg
Potassium	415 mg
Magnesium	43 mg
Manganese	0.23 mg

Sources: USDA Food Data [29], [30].

1.5 Ginger and Functional Dyspepsia

Regarding gastrointestinal health, ginger has long been utilized across the globe. Experimental studies suggest that the nutritive and bioactive compounds in it enhance gastrointestinal motility, modulate serotonin receptors, and possess antiemetic and anti-inflammatory effects[29]. For instance, a randomized controlled trial by Wu et al. [34] demonstrated that ginger significantly increased antral contractions and accelerated gastric emptying in healthy adults. Similarly Hu et al.[5] observed notable improvements in bloating and early satiety among patients with functional dyspepsia following ginger supplementation.

Evidence indicates that ginger may alleviate hallmark symptoms of FD, such as delayed gastric emptying, bloating, and nausea, by improving gastric motility [5]. It is also commonly

recommended for various gastrointestinal complaints, including flatulence, abdominal cramps, diarrhea, and spastic colon, as well as for non-gastrointestinal conditions such as headaches, nausea, and motion sickness [25,35]. Ginger root is rich in a variety of nutrients, including para-aminobenzoic acid, manganese, choline, folic acid, inositol, B vitamins, vitamin C, and essential oils [29]. Nevertheless, systematic reviews have highlighted significant heterogeneity in clinical trial designs, ginger dosages, and outcome measures, underscoring the need for more standardized and methodologically rigorous research [25,36].

1.6 Ginger on Fat Loss and Anthropometric Parameters

Beyond its role in gastrointestinal health, ginger has been recognized for its metabolic-enhancing and fat-reducing properties. The co-occurrence of functional dyspepsia (FD) and obesity presents a complex clinical scenario, characterized by overlapping symptoms and shared underlying mechanisms. While ginger supplementation has shown promise in managing FD symptoms and modulating body composition in others [37–39], the impact of ginger on body fat content in patients with FD remains inadequately explored.

Several studies have [7,37,40] suggested that ginger consumption may aid in weight management by promoting thermogenesis, enhancing lipid metabolism, and regulating appetite hormones. Since excess adiposity is associated with increased FD symptom severity and systemic inflammation, dietary ginger supplementation may offer a dual benefit: symptom relief and improved body composition, making it a valuable nutritional intervention for patients with FD. Although FD is not directly categorized under metabolic disorders, emerging evidence suggests that excess body fat, particularly visceral adiposity, may exacerbate dyspeptic symptoms through both mechanical and hormonal pathways [3,16]. These findings have led to growing interest in exploring interventions that may concurrently alleviate gastrointestinal symptoms and contribute to body fat reduction. Ginger has been widely used

in traditional medicine for its therapeutic properties. It contains several biologically active compounds, notably gingerols, shogaols, and paradols, which exhibit anti-inflammatory, antioxidant, antiemetic, and prokinetic effects [27]. These compounds are known to enhance gastric emptying, stimulate digestive enzymes, and regulate gut motility functions that are particularly relevant for patients with FD. Studies have demonstrated that ginger has a positive impact on gastrointestinal motility and dyspeptic symptoms. For example, Wu et al. [34] found that ginger significantly accelerated gastric emptying and reduced sensations of fullness in healthy individuals. Similarly, Borrelli et al.[36] reported improvements in gastrointestinal discomfort and motility in FD patients after ginger supplementation.

Recent clinical interest has also focused on ginger's role in weight management and body fat reduction. Several randomized controlled trials and meta-analyses have shown that ginger supplementation can result in modest but statistically significant decreases in body weight, BMI, waist circumference, and overall fat mass among overweight or obese individuals [7], [41].The proposed mechanisms include increased thermogenesis, enhanced lipolysis, improved insulin sensitivity, and appetite regulation[42]. In one meta-analysis, ginger intake ranging from 1 to 3 grams per day over 8 -12 weeks was found to significantly reduce adiposity indicators and improve metabolic parameters [7]. These effects are particularly promising given the rising prevalence of obesity-related gastrointestinal complaints.

Despite separate streams of evidence demonstrating ginger's efficacy in treating dyspeptic symptoms and in reducing body fat, studies that specifically examine its impact on body fat loss among patients with functional dyspepsia remain scarce. This represents a significant gap in the literature, as individuals with FD may exhibit altered satiety signaling and digestive function, potentially influencing their body composition and response to dietary interventions. Given that visceral fat contributes to gastrointestinal dysmotility and increases inflammatory

mediators that can worsen FD symptoms, targeting fat loss through ginger supplementation may provide dual therapeutic benefits[43]. Preliminary results from a clinical trial conducted by Aregawi et al. [44] showed that ginger improved quality of life and symptom scores in FD patients. Although changes in body composition were not the primary outcome, the findings suggested a trend toward improved metabolic markers, supporting the rationale for further investigation.

1.7 Ginger's Mechanism of Action

Ginger exerts its beneficial effects on FD and body fat management through multiple mechanisms

1.7.1 Ginger's Mechanisms of Action in FD

A. Prokinetic Effects: Enhancing Gastric Motility

Gingerols and shogaols stimulate antral contractions and accelerate gastric emptying, thereby alleviating postprandial distress [34]. Additionally, ginger modulates cholinergic and serotonergic pathways, both of which play crucial roles in gastric motility regulation. By enhancing these pathways, ginger improves gastric motility and reduces symptoms associated with delayed gastric emptying [5].

B. Anti-Inflammatory and Antioxidant Properties

Gingerols and shogaols exhibit anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF- α , IL-6, and COX-2, thus reducing gastric mucosal inflammation[45]. Furthermore, ginger's potent antioxidant properties help lower oxidative stress, which is a contributing factor in gastric mucosal damage and FD symptoms [46].

C. Reduction of Visceral Hypersensitivity and Pain

Ginger interacts with transient receptor potential vanilloid 1 (TRPV1) channels, which are involved in gastric hypersensitivity and pain perception. This interaction helps in reducing gastric pain and discomfort commonly experienced in FD [47]. Clinical studies further confirm that ginger supplementation is associated with a significant reduction in epigastric pain and postprandial distress [48].

D. Stimulation of Digestive Enzyme Secretion

Ginger enhances the secretion of digestive enzymes such as amylase, lipase, and protease, which improve digestion and facilitate nutrient absorption[28]. Additionally, ginger promotes bile acid secretion, aiding in fat digestion and reducing bloating, a common symptom in FD patients [49].

E. Anti-Nausea and Carminative Properties

Ginger has been found to act as a 5-HT₃ receptor antagonist, thereby reducing nausea and vomiting, which are frequently associated with FD [25]. Additionally, ginger possesses carminative properties, preventing excessive gas accumulation in the intestines and helping alleviate bloating and discomfort [26].

1.7.2 Ginger's Mechanisms of Action in Fat Loss and obesity

Fat loss interventions often target energy balance, metabolic rate, appetite regulation, and hormonal control. Ginger has been identified as a natural agent with multifactorial benefits.

A. Thermogenesis and Lipolysis

Ginger enhances thermogenesis by increasing norepinephrine levels and stimulating β -adrenergic receptors, promoting lipolysis [50]. Ginger activates AMPK (AMP-activated protein kinase), a key regulator of fat metabolism, promoting fatty acid oxidation and inhibiting lipogenesis. It has been shown to increase energy expenditure and fat oxidation. Mansour et al. [41] reported that ginger supplementation elevated resting metabolic rate (RMR) in overweight individuals.

B. Appetite Regulation and Satiety

Ginger increases satiety and reduces hunger scores, likely by enhancing levels of GLP-1 and peptide YY, while suppressing ghrelin[41]. This leads to reduced calorie intake, promoting gradual fat loss. Ginger may modulate appetite hormones such as leptin and ghrelin, promoting satiety and reducing calorie intake [51].

C. Insulin Sensitivity and Glucose Regulation

Insulin resistance is a risk factor for obesity, and ginger has been found to enhance glucose metabolism, potentially aiding in weight management among FD patients [52]. Ginger reduces fasting blood glucose, improves insulin sensitivity, and increases adiponectin levels [51]. These actions support weight loss by improving glucose utilization and reducing fat storage.

D. Anti-Inflammatory Action in Obesity

Obesity is associated with chronic low-grade inflammation. Ginger reduces CRP, IL-6, and TNF- α , creating a more favorable metabolic environment for fat loss [42].

E. Inhibition of Fat Absorption

Some ginger compounds (e.g., 6-gingerol) have been shown in vitro to inhibit pancreatic lipase, reducing the digestion and absorption of dietary fat [53]. A meta-analysis by Mozaffari-

Khosravi et al. [7] , concluded that ginger supplementation significantly reduced body weight, waist-to-hip ratio, and body fat percentage in overweight and obese individuals.

Table 3. Summary of Mechanism of ginger

Role of ginger	Mechanism	References
FD Management	Gastric motility ↑, inflammation ↓	Hu et al.; Aregawi et al. [5], [44]
Anti-nausea	5-HT3 receptor antagonism	Lete & Allué [39]
Weight loss	Thermogenesis, appetite ↓	Maharlouei et al. [7]
Anti-inflammatory	NF-κB, IL-6, TNF-α inhibition	Abolfathi et al. [54]
Insulin sensitivity	Improves glucose uptake	Mansour et al.[41]

1.8 Tolerability and Safety of Ginger Supplementation

Ginger is generally regarded as safe by the U.S. Food and Drug Administration (FDA) [55] and clinical trials report few adverse effects, most of which are mild and transient, such as gastrointestinal irritation or heartburn [30]. Studies involving daily doses ranging from 1 to 2 grams have shown high compliance and minimal dropouts due to side effects[56]. Nevertheless, evaluating adverse effects and tolerability in a specific patient group, such as those with FD, remains essential for clinical recommendations. Despite its long-standing traditional use, the clinical evidence regarding ginger’s effectiveness and safety in FD management remains limited and inconclusive. Moreover, few studies have explored its potential to reduce body fat or documented adverse effects and tolerability in patients with FD.

This study aims to assess the effects of dietary ginger supplementation on dyspeptic symptoms, fat loss, and the safety profile of ginger supplementation in FD patients.

1.9 Rationale of the Study

Functional dyspepsia (FD) is a common gastrointestinal disorder that significantly impairs quality of life and affects up to 40% of the global population [1]. Conventional pharmacological treatments often have limited effectiveness and may cause adverse effects, prompting increased interest in dietary and natural alternatives [1].

Ginger (*Zingiber officinale*), a nutrient-rich root, contains bioactive compounds such as gingerols and shogaols, which have demonstrated anti-inflammatory, antioxidant, and gastroprotective effects [29,46]. These compounds are known to enhance gastric emptying and reduce visceral hypersensitivity, thereby potentially alleviating dyspeptic symptoms[5]. In addition to its digestive benefits, ginger may aid in fat metabolism and weight loss by influencing thermogenesis and lipid oxidation [51,57]. This is particularly relevant for FD patients, as abdominal adiposity has been associated with worsened gastrointestinal symptoms and reduced treatment response[16].

Improving both gastrointestinal symptoms and metabolic outcomes may lead to enhanced quality of life, an essential aspect of holistic FD management [3]. However, clinical data evaluating the efficacy and safety of ginger supplementation in FD patients are limited. This study, therefore, aims to assess the effects of dietary ginger supplementation on functional dyspepsia symptoms, fat loss, safety, and quality of life, contributing to the evidence for ginger as a safe and functional dietary intervention in FD management.

2. STUDY OBJECTIVES

The main aim of this study was to evaluate the effects of dietary ginger supplementation on functional dyspepsia symptoms and fat loss among patients with functional dyspepsia. To address the aim, the following objectives were set:

- To assess the impact of dietary ginger supplementation on the severity and frequency of functional dyspepsia symptoms
- To evaluate changes in quality of life following dietary ginger supplementation in patients with functional dyspepsia
- To determine the effect of dietary ginger supplementation on body composition, particularly fat loss, in patients with functional dyspepsia.
- To assess the tolerability and potential side effects of dietary ginger supplementation in patients with functional dyspepsia.

RESEARCH QUESTIONS

The main research questions that guided this study were:

1. Does dietary ginger supplementation reduce the severity and frequency of functional dyspepsia symptoms?
2. How does ginger supplementation influence the quality of life of patients with functional dyspepsia?
3. What is the effect of dietary ginger supplementation on body fat composition in patients with functional dyspepsia?
4. Is dietary ginger supplementation well-tolerated, and what are the potential side effects?

3. MATERIALS AND METHODS

3.1 Study design

Pre and post-intervention evaluations were carried out over an eight-week period in this single-center, open-label clinical experiment. Patients having a diagnosis of functional dyspepsia at the University of Debrecen's Internal Medicine Outpatient Department in Debrecen, Hungary, participated in the study. All participants were diagnosed based on the Rome IV criteria for Functional Dyspepsia [3].

The reason for the choice of an open-label design instead of a randomized controlled trial (RCT) with a placebo group was particularly due to the onset of the COVID-19 pandemic at the start of our study. The pandemic posed significant challenges related to participant recruitment, safety protocols, resource allocation and the procurement of placebo materials, all of which made it unfeasible to implement a double-blind, placebo-controlled design during that period. Conducting a randomized controlled trial with a placebo group would have required additional time, funding and material to develop, produce and validate a suitable placebo that closely mimics the appearance, taste, and smell of ginger. Given the pandemics the limited time and resources available during the study period, an open-label design was the most feasible approach to initiate clinical investigation. While we recognize the limitations associated with the lack of blinding, especially the potential for placebo effects in a condition like Functional Dyspepsia, we sought to mitigate bias through the use of validated outcome measures and consistent follow-up procedures. This design allowed us to conduct a preliminary evaluation of ginger supplementation under constrained conditions. Moving forward, we recommend for a randomized, double-blind, placebo-controlled trial to strengthen the evidence and validate our findings under more controlled circumstances.

3.2 Study Participants

The study involved the recruitment of 62 participants with functional dyspepsia, 51 of whom completed the study. Prior to and after eight weeks of ginger administration, a self-administered questionnaire was used to gather data during hospital visits. Based on the existence of functional dyspepsia symptoms reported at the initial appointment, eligibility for inclusion was determined. Written informed consent was given by each subject, and participation was completely voluntary.

3.2.1 Inclusion Criteria:

- Adult patients aged 18–72 years.
- Diagnosed with functional dyspepsia based on Rome IV criteria.
- Symptomatic for at least 3 months prior to the study.
- Stable weight for the past three months (± 2 kg)
- Not taking any drugs that could affect the trial's results, such as proton pump inhibitors or H2 receptor antagonists.

3.2.2 Exclusion Criteria:

- Individuals suffering from organic gastrointestinal conditions (such as with malignancy, GERD, or peptic ulcer disease).
- Women who are nursing or pregnant
- A history of allergic responses to supplements containing ginger.
- Individuals who are on weight loss or drugs that have been shown to interact with ginger, such as anticoagulants.

- Use of weight-loss medications or supplements
- Severe dyspeptic symptoms requiring immediate pharmacological intervention

3.3 Randomization and masking

This single-center, open-label clinical trial involved a single arm treatment group receiving ginger supplementation. Given the study's single arm design, traditional methods such as randomization into multiple treatment arms and blinding were not applicable. However, to enhance validity and reduce potential bias, we implemented specific measures: (A) Randomization of Treatment Timing: Although ginger supplements were given to all subjects, we varied when they began taking them. This could assist in adjusting for any confounding variables or temporal effects. To minimize potential confounding factors, we took some steps to ensure that participants' lifestyle habits, particularly diet and physical activity, remained stable throughout the study period.

At baseline, participants were instructed to maintain their usual dietary patterns and levels of physical activity during the 8-week intervention. This instruction was emphasized both verbally and in writing during the enrollment process and reinforced at each follow-up visit. Throughout the study, we conducted regular weekly follow-up contacts by phone, during which participants were asked about any significant changes to their diet, exercise routines, or the use of new supplements or medications. Any reported deviations were documented and monitored closely. Participants were also reminded during each contact to avoid making lifestyle changes that could influence the study outcomes. While we did not implement objective measures (e.g., food diaries or activity trackers), these consistent reminders and monitoring efforts were intended to support compliance and reduce variability related to lifestyle factors.

3.4 Procedures

3.4.1 Intervention

A ready-made Swanson 540 mg ginger root extract capsule, Budapest, Hungary, was used, following the established protocol. Swanson 1080 mg/day, twice day, which is 540 mg of ginger root extract, Budapest, Hungary, a ready-made ginger capsule supplement, was administered to the trial participants. The patients who were enrolled were told to take two 540 mg capsules for eight weeks, one half an hour before lunch and one before dinner. All patients were instructed to refrain from taking prokinetic and anti-secretory drugs for the entire eight weeks that they were taking ginger supplements prior to the start of the experiment. Throughout the study period, study participants were encouraged to continue their typical food and activity habits.

Swanson Ginger Root 540 mg supplement

The ginger supplement we used in our study was commercially available standardized Swanson Ginger Root capsule (Swanson Health Products, Budapest, Hungary).

Formulation: Each capsule contained 540 mg of dried ginger root powder (*Zingiber officinale*).

Type: Whole-root powdered form, not a concentrated extract

Solubility: As a dried powder, ginger is partially water-soluble, but active components such as gingerols and shogaols are more soluble in ethanol or lipids.

Dose Administered: Participants received 2 capsules of each 540 mg per day, corresponding to a total daily dose of 1,080 mg.

Composition (Based on Manufacturer):- The composition of the Swanson ginger root capsules, based on manufacturer information, typically includes 6-gingerol (0.5–1.5%), 6-

shogaol (0.1–0.5%), essential oils (1.0–3.0%), trace amounts of zingerone (up to 0.1%), with fiber and starch as the major bulk components, along with other phenolic compounds present in minor amounts.

Material for Capsules: Gelatin obtained from cows is used to make the capsules. Most people tolerate gelatin capsules well, and they are frequently seen in dietary supplements. But it's crucial to remember for people who have religious convictions that exclude consuming goods made from cows or who adhere to particular dietary restrictions.

Free of Common Allergens: Those who prefer natural supplements can use this product because it is devoid of artificial colors, flavors, and preservatives. For those who have dietary sensitivities or allergies, it is also devoid of common allergens like wheat, peanuts, eggs, fish, tree nuts, soy, milk, and shellfish.

3.4.2 The Nepean Dyspepsia Index (NDI)

It has been demonstrated that the Nepean Dyspepsia Index (NDI), which was created in the late 1990s to gauge the impact of functional dyspepsia on quality of life, has clinical significance [58], [59]. It assesses the entire impact of dyspepsia on patients' well-being, taking into account elements such as the intensity of symptoms, emotional state, disruption of daily activities, and general health satisfaction. [58]. It stems from the Nepean Dyspepsia Index and is designed to assess the quality of life in functional dyspepsia [59]. A 5-point Likert scale, ranging from 1 ('not at all' or 'not applicable') to 5 ('very'), is used to rate each item. Each subscale's individual item scores are added together to provide a total score that ranges from 10 (lowest) to 100 (highest). According to the tool's developers, a higher SF-NDI score denotes a lower quality of life, with values above >15 indicating a markedly lower health-related quality

of life. Numerous studies and populations have used the NDI extensively, proving its validity and reliability in determining how dyspepsia affects quality of life. [60], [61].

3.4.3 The IN-Body 720 Body Composition Analyzer

In this study body composition was analyzed using the INBODY 720. The In-body 720 is a body composition analyzer that utilizes bioelectrical impedance analysis (BIA) technology to measure various components of body composition. It offers detailed insights into body fat, muscle mass, water distribution, and more. It is widely used in clinical settings, fitness centers, sports medicine, and research. It helps professionals track patients' or clients' body composition changes over time, especially in programs related to weight management, muscle development, or chronic disease management. The measurement process is non-invasive, quick (typically under a minute), and does not require the patient to undress, making it convenient for repeated use over time. Due to its high precision and segmental analysis capabilities, the In-Body 720 is considered one of the more advanced tools available for body composition analysis, particularly useful in clinical trials or research involving changes in body composition Figure 1.



Figure 1. InBody720 Body Composition Analyzer

3.5 Outcome Measures

The study assessed multiple outcomes to evaluate the impact and safety of the intervention over an eight-week period. Quality of life related to dyspeptic symptoms was measured using the Short-Form Nepean Dyspepsia Index (NDI) questionnaire, administered at both baseline and at the end of the intervention. This tool includes 10 items rated on a 5-point Likert scale, where higher scores reflect greater impairment in quality of life. The total score ranges from 0 to 50.

In addition to quality of life, the study evaluated physiological and symptomatic changes. These included body fat percentage, assessed via bioelectrical impedance analysis (BIA), as well as body weight and waist-to-hip ratio (WHR). Changes in the frequency and severity of dyspeptic

episodes were also tracked, using the NDI to capture symptom improvement. All measurements were recorded at baseline and repeated after the eight-week intervention period.

Furthermore, adverse events and tolerability were systematically monitored throughout the study. Participants were asked to report any side effects or unusual symptoms during scheduled follow-up visits and via direct contact when necessary. The nature, frequency, and severity of any reported adverse events were recorded and evaluated to assess the safety and tolerability of the intervention.

- A. Improvement in Functional Dyspepsia (FD) Symptoms and Quality of Life (QoL):
Assessed using the Nepean Dyspepsia Index (NDI) at baseline and post intervention.
Reduction in symptom severity scores, including postprandial fullness, early satiety, bloating, and epigastric pain.
- B. Fat Loss and Body Composition Changes: Measured at baseline and post-intervention. Body Mass Index (BMI, kg/m²), Waist circumference (cm) and Body fat percentage (%), assessed using bioelectrical impedance analysis (BIA), the IN-Body 720 Body composition analyzer.
- C. Adverse Events and Tolerability: Assessed at baseline and post-intervention with close follow-ups. Frequency and type of reported side effects (dyspepsia symptoms and allergic reactions). Compliance rate with ginger supplementation measured via pill count

3.6 Ethical clearance

This study was conducted in full compliance with the ethical principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the University of Debrecen, registry reference number: DE RKEB/IKEB 5622-2020 and registered in [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT06313814), NCT06313814. Prior to being included in the study, each participant gave

written informed consent attesting to their voluntary involvement and comprehension of the goals, methods, risks, and advantages of the research. The freedom to leave the study at any time without facing any repercussions was guaranteed to the participants. All personal data was anonymized, and research records were safely kept to preserve their privacy. The participants were given a thorough explanation of any small hazards related to taking ginger supplements. Any unanticipated problems were resolved immediately to guarantee participant safety, and no negative effects beyond those typically linked to ginger use were anticipated. This study aimed to contribute to the growing body of knowledge regarding the use of herbal supplements in improving the quality of life in patients with functional dyspepsia while maintaining a high standard of ethical conduct throughout the research process.

3.7 Data analysis

All statistical analyses were conducted using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were employed to summarize baseline demographic and clinical characteristics, as well as adherence rates to ginger supplementation. Continuous variables, such as age, BMI, symptom severity, and body fat percentage, were presented using mean, median, standard deviation, and range. Categorical variables, including gender distribution, anthropometric and clinical symptoms were summarized using frequencies proportions and percentages.

To assess the effectiveness of the intervention, both descriptive and inferential statistical methods were utilized. Changes in outcomes, such as quality of life scores, symptom severity, body fat percentage, and other physiological indicators, were analyzed by comparing pre- and post-intervention values. For normally distributed data, the paired t-test was applied, while the Wilcoxon signed-rank test was used for non-normally distributed data. A p-value of less than 0.05 was considered statistically significant.

Adverse events and tolerability data were analyzed descriptively. The frequency and type of reported side effects were summarized using counts and percentages. Participant-reported tolerability was categorized as good, moderate, or poor based on self-reports and study monitoring.

4. RESULTS

4.1. Socio-demographic and Baseline Characteristics of Study Subjects

A total of 62 participants with functional dyspepsia were enrolled in the study. Of these, 51 participants completed the 8-week intervention with daily dietary ginger supplementation (1.080 grams/day). Eleven patients were lost to follow-up due to non-compliance and unrelated health issues *Figure 2*. The mean age of participants was 49.74 ± 16.4 years and the mean BMI was 25.66 ± 4.9 kg/m² at baseline. The baseline characteristics of the study participants are shown in *Table 4*. Data analysis was performed on the 51 participants who completed the study.

Table 4. Baseline sample characteristics (n=51)

Parameters	
Gender Male	11(21.6%)
Female	40(78.4%)
Age	49.74±16.4
BMI	25.66±4.90
WHR	0.92 ± 0.82
PDS	29.0(57.0%)
EPS	33.0(64.7%)

BMI-Body Mass Index, WHR-Waist Hip Ratio, PDS- Postprandial Distress Syndrome, EPS-Epigastric Pain Syndrome, gender, PDS and EPS are presented as number (N) and percentage (%) and Age, BMI and WHR are presented as mean and standard deviation




Figure 2. Flow diagram of study subjects

4.2. Effects of Ginger on Functional Dyspepsia Symptoms and Quality of Life

The influence of ginger supplementation on the quality of life in patients diagnosed with functional dyspepsia was evaluated using the Nepean Dyspepsia Index (NDI) questionnaire. At baseline, participants completed the NDI-SF to establish initial measures of dyspeptic symptoms and quality of life. Following an 8-week intervention period, the same questionnaire was administered to assess post-intervention outcomes. Quality of life, assessed using the Nepean Dyspepsia Index (NDI), improved following the intervention. Mean total NDI score

improved from 19.07 ± 23.2 at baseline to 9.10 ± 19.3 at week 8 ($p < 0.05$), indicating enhanced daily functioning and reduced symptom-related distress. Subscales reflecting interference, eating and drinking habits, and daily activity impact (work) showed statistically significant improvements ($p < 0.05$ for all domains). The analysis revealed a statistically significant improvement in both dyspeptic symptoms *Figure 3*, and quality of life *Table 5* from baseline to the 8-week follow-up.

Table 5. Nepean Dyspepsia Index (NDI) scores at baseline and eight weeks of ginger supplementation.

NDI parameters	Baseline (mean \pm SD)	After 8wks (mean \pm SD)	Change in score	p-value
Tension	9.20 (22.6)	7.1(16.7)	-2.1(30.95)	0.670
Interference	14.5 (24.7)	6.7(20.2)	-7.8(22.45)	0.020*
Eat/drink	15.1(25.3)	7.4(16.1)	-7.7(20.70)	0.013*
Knowledge	5.70(21.4)	2.7(15.4)	-3.0(18.40)	0.524
Work	12.7(24.5)	5.4(19.8)	-7.3(22.15)	0.010*
Total	19.07(23.2)	9.10(19.3)	-9.97(16.20)	0.039*

NDI – Nepean Dyspepsia Index SD; Standard Deviation

Values are presented as mean \pm SD

* $P < 0.05$




Figure 3. Frequency distribution of dyspeptic symptoms at baseline and eight weeks of ginger supplementation

4.3. Effects of Ginger on Fat Loss and Anthropometric Parameters

In our study, the Body Composition Analyzer (IN Body 720) provided a measurement of a wide range of body composition parameters. These included total body weight, fat mass, skeletal muscle mass (SMM), percent body fat (%BF), visceral fat level, body mass index (BMI), waist-hip ratio (WHR), body water (BW), basal metabolic rate (BMR), and segmental analysis of fat and lean mass in each limb and the trunk.

Ginger supplementation may influence some of these parameters, primarily through its thermogenic, anti-inflammatory, and digestive properties. For example, ginger has been shown to promote fat metabolism and appetite regulation, which can lead to reductions in fat mass, percent body fat, and visceral fat levels. Its anti-inflammatory effects may contribute to improvements in the body water ratio, especially in individuals with fluid retention or low-grade inflammation. Additionally, ginger may modestly enhance energy expenditure,

potentially reflected as a slight increase in BMR. However, significant changes in muscle mass or total body weight are less likely unless combined with dietary or physical activity interventions.

Although the In-Body 720 provides a wide range of body composition parameters, in our study, we recorded all available parameters but focused our analysis on specific ones relevant to the research objectives. These included body weight (wt), body mass index (BMI), waist-hip ratio (WHR), percent body fat (%BF), and body fat mass. These parameters were selected to evaluate the potential effect of ginger supplementation on body composition indicators and body fat distribution.

Ginger supplementation showed minimal changes in body composition. The average body fat percentage decreased slightly from 26.8 ± 3.4 at baseline to 25.9 ± 3.1 after 8 weeks; however, this difference was not statistically significant ($p = 0.173$). Likewise, there were no significant changes in body weight or BMI over the 8-week period (mean change: 0.5 ± 1.1 kg, $p = 0.24$) as presented in Table 6.

Table 6. Changes in body fat and anthropometric parameters after 8 weeks of ginger supplementation (n=51)

Parameters	Baseline	At 8 weeks	P-value
Body mass index (BMI)	25.66±4.90	26.15±5.10	0.240
Waist hip ratio (WHR)	0.92 ± 0.82	0.91±0.73	0.410
Body fat percent (BF%)	26.8 ± 3.4	25.9 ± 3.1	0.173
Body fat mass in Kg	27.6±2.6	27.01 ± 2.1	0.324

SD; standard deviation; BMI-body mass index; WHR; waist-hip ratio
Values are presented as mean ± SD

4.4. Detailed Body Composition Metrics (IN-Body 720)

Body composition was analyzed a lot of parameters. Following 8 weeks of daily ginger supplementation (1.080 g/day), no significant changes were observed in body composition metrics. Although minor variations were noted in weight, body fat percentage, and skeletal muscle mass, none reached statistical significance ($p > 0.05$) Table 7.

Table 7, Full body composition before and after Ginger supplementation (n=51)

Parameters	Baseline(mean ± SD)	8 Weeks(mean ± SD)	Change	P-value
Body weight(kg)	65.1 ± 10.2	65.6 ± 10.0	+0.5	0.240
Fat mass(Kg)	27.6 ± 2.60	27.0 ± 2.1	-0.6	0.324
Skeletal Muscle Mass(kg)	22.8 ± 3.10	22.9 ± 3.1	+0.1	0.386
Percent body fat(%)	26.8 ± 3.40	25.9 ± 3.1	-0.9	0.173
Visceral fat level	10.4 ± 1.8	10.2 ± 1.7	-0.2	0.447
BMI(Kg/m ²)	25.66 ± 4.90	26.15 ± 5.10	+0.49	0.240
Waist Hip Ratio(WHR)	0.92 ± 0.82	0.91 ± 0.73	-0.01	0.410
Body water(L)	32.9 ± 3.40	33.2 ± 3.5	+0.3	0.291
Basal Metabolic rate(Kcal/day)	1310 ± 150	1320 ± 148	+10	0.393

4.5 Segmental Fat and Lean Mass Analysis

Segmental analysis of body composition showed minimal reductions in regional fat mass across limbs and trunk. Lean mass remained stable, and all observed differences were statistically non-significant ($p > 0.3$). This supports the conclusion that ginger supplementation had no significant effect on localized fat or muscle mass Table 8.

Table 8. Segmental Fat and Lean Mass Before and After Ginger Supplementation (n=51)

Body part	Fat mass (kg)(Mean ± SD)		P-value	Lean Mass (kg)(Mean ± SD)		P-value
	Before	After		Before	After	
Right arm	1.45± 0.22	1.41 ± 0.20	0.312	2.90 ±0.30	2.90 ± 0.29	0.842
Left arm	1.43 ±0.21	1.40 ± 0.19	0.354	2.80 ± 0.31	2.80 ± 0.30	0.813
Trunk	12.8± 1.60	12.5 ± 1.50	0.282	19.3 ± 2.40	19.4 ± 2.40	0.420
Right leg	4.20 ±0.38	4.10 ± 0.36	0.370	6.70 ±0.52	6.70 ± 0.51	0.898
Left leg	4.10 ±0.35	4.00 ± 0.36	0.362	6.60 ± 0.54	6.60 ± 0.53	0.876

4.6. Overall Changes in Body Composition

After 8 weeks of ginger supplementation, no statistically significant changes were observed in body composition. BMI slightly increased from 25.66 ± 4.90 to 26.15 ± 5.10 kg/m² ($p = 0.240$). BF% decreased from $26.8 \pm 3.4\%$ to $25.9 \pm 3.1\%$ ($p = 0.173$), while fat mass decreased from 27.6 ± 2.6 kg to 27.01 ± 2.1 kg ($p = 0.324$). WHR also decreased slightly (from 0.92 ± 0.82 to 0.91 ± 0.73), but the change was not significant ($p = 0.410$).

4.7. Subgroup Comparisons

The main influencing factors that could affect the effectiveness of ginger supplementation on the analyzed body composition parameters in our study include age, BMI, Body fat percentage, and duration of intervention. Age plays a role, as older adults may gain more benefits from ginger's anti-inflammatory and digestive properties. Body mass index (BMI) and overall body weight are also important, with individuals having a higher BMI potentially experiencing more significant reductions in fat mass and appetite regulation. A higher body fat percentage offers

more room for fat reduction, making such individuals more responsive. Similarly, those with elevated visceral fat levels may exhibit greater improvements due to ginger's thermogenic and fat metabolism-enhancing effects. Gender differences may influence the response due to variations in fat distribution and hormonal regulation. Another one could be duration of supplementation, longer durations may tend to produce greater and more sustained improvements in the measured body composition parameters.

4.7.1. Comparison by sex

At baseline, female participants had a significantly higher body fat percentage and BMI compared to males ($p < 0.05$). After 8 weeks, both sexes experienced modest and statistically non-significant changes in body composition. Females showed an average reduction in BF% of $-0.8 \pm 2.1\%$, while males demonstrated a slightly greater decrease of $-1.1 \pm 2.9\%$ ($p = 0.622$ for between-group comparison). Changes in BMI and WHR were comparable between groups, with no significant differences observed Table 9.

Table 9. Ginger's Effect Comparison by Sex (n=51)

Parameter	Females (n=40)	Males (n=11)	P-value
BMI change (kg/m ²)	+0.49 ± 1.0	+0.51 ± 1.3	0.912
BF% change	-0.8 ± 2.10	-1.1 ± 2.9	0.622
BF mass change (kg)	-0.55 ± 1.7	-0.69 ± 2.0	0.768
WHR change	-0.01 ± 0.08	-0.01 ± 0.10	0.955

Both males and females experienced slight, non-significant improvements in fat-related parameters. No significant sex differences in response to ginger supplementation were observed.

4.7.2. Comparison by age group

Participants were stratified into two groups: those under 50 years ($n = 26$) and those aged 50 years or older ($n = 25$). Younger participants had a slightly greater reduction in BF% ($-1.0 \pm 2.3\%$) compared to older participants ($-0.7 \pm 2.5\%$), but the difference was not statistically significant ($p = 0.648$). Changes in BMI, WHR, and body fat mass were similarly non-significant between the age groups Table 10.

Table 10. Comparison by age group (<50 years VS >50 years)

Parameter	<50 years (n=26)	≥50 years (n=25)	p-value
BMI change (kg/m ²)	+0.44 ± 1.0	+0.53 ± 1.2	0.725
BF% change	-1.0 ± 2.3	-0.7 ± 2.5	0.648
BF mass change (kg)	-0.62 ± 1.7	-0.56 ± 1.9	0.861
WHR change	-0.01 ± 0.09	-0.01 ± 0.09	0.998

There were no statistically significant differences between age groups. Slightly greater fat loss was observed in participants under 50, but it did not reach statistical significance.

4.7.3 Comparison by BMI Category

Participants were categorized based on baseline BMI as: Normal weight (18.5–24.9 kg/m²): $n = 24$ and Overweight/Obese (≥ 25 kg/m²): $n = 27$. No statistically significant differences were found between BMI categories. However, overweight/obese participants showed slightly greater reductions in BF% and fat mass, though these did not reach significance Table 11.

Table 11. Comparison by Body Mass Index (BMI) category (n=51)

Parameter	Normal BMI (n = 24)	Overweight/Obese (n = 27)	p-value
BF% change	-0.6 ± 2.0	-1.1 ± 2.7	0.474
Fat mass change (kg)	-0.48 ± 1.6	-0.68 ± 1.9	0.621
BMI change (kg/m ²)	+0.35 ± 0.9	+0.62 ± 1.2	0.367
WHR change	-0.01 ± 0.08	-0.01 ± 0.09	0.934

4.8. Reported adverse effects and Tolerability

Ginger supplementation was generally well tolerated by participants. Mild gastrointestinal side effects were mostly observed during the first week of the intervention and resolved on their own without the need for medical treatment. No serious adverse events occurred throughout the study. The most frequently reported side effects included mild bloating (14.9%), heartburn (12.8%), and diarrhea (10.6%), all of which were temporary and self-limiting. Importantly, no participants discontinued the ginger supplementation due to these effects. Additionally, one participant experienced a mild headache that subsided without any intervention Table 12.

Table 12. Adverse effects frequency and percentage (n=47)

Parameters	Frequency	Percentage
Bloating	7	14.9%
Heartburn	6	12.8%
Diarrhea	5	10.6%
Headache	1	2.1%

Tolerability

At the end of the study, 87.2% of patients rated the tolerability of ginger supplementation as good or excellent. No patient rated tolerability as poor or very poor Table 13.

Table 13. Tolerability Rating and Percentage (n=47)

Parameters	N	%
Excellent	18	38.3%
Good	23	48.9%
Moderate	6	12.8%
Poor	0	0%
Very Poor	0	0%

5. DISCUSSION

This study investigated the effects of dietary ginger supplementation on functional dyspepsia symptoms, quality of life, fat loss, and adverse effects among patients with FD. The outcomes provide promising evidence that ginger supplementation over an 8-week period significantly improves both dyspeptic symptoms and patients' quality of life, with high tolerability and minimal adverse effects.

5.1 Ginger's Impact on Functional Dyspepsia Symptoms and Quality of Life

The results demonstrated a significant improvement in functional dyspepsia symptoms and associated quality of life, as measured by the Nepean Dyspepsia Index (NDI). Total NDI scores improved markedly from baseline to the 8-week follow-up (mean change: -9.97, $p = 0.039$), reflecting enhanced daily functioning and reduced dyspeptic symptom-related distress. Notably, statistically significant improvements were observed in the subdomains of interference ($p = 0.020$), eating and drinking habits ($p = 0.013$), and work-related impacts ($p = 0.010$), which are core components affecting patients' daily experiences with FD. The observed improvements in symptom frequency and severity *Figure 3*, further support ginger's potential as an effective natural therapy in managing FD.

These results align with previous clinical and preclinical studies suggesting that ginger possesses prokinetic, antiemetic, and anti-inflammatory properties that may contribute to symptom relief in functional gastrointestinal disorders. A comprehensive review and meta-analysis demonstrated that dyspeptic patients who consumed ginger showed a significant improvement in gastric emptying compared to those in the placebo group [5]. Additionally, ginger extract was found to enhance stomach emptying in healthy individuals, although this effect was observed only at higher doses[48]. Other studies have also explored ginger's

potential impact on dyspepsia. In one double-blind, randomized trial, ginger significantly alleviated dyspeptic symptoms. Furthermore, another randomized controlled study reported that a combination of ginger and artichoke extract markedly reduced dyspepsia symptoms compared to a placebo [38].

The benefits of ginger may be attributed to its anti-inflammatory, antioxidant, and antiemetic properties. These characteristics likely aid in relieving gastrointestinal inflammation, promoting healthy gastric motility, and alleviating symptoms of functional dyspepsia. Compounds such as gingerols found in ginger have been shown to suppress the production of pro-inflammatory cytokines and enzymes that drive inflammation, thereby helping to reduce irritation in the stomach lining. Research indicates that ginger's anti-inflammatory effects on the gastrointestinal system could be valuable in managing conditions like inflammatory bowel disease, gastritis, and gastric ulcers. Its ability to inhibit the synthesis of pro-inflammatory cytokines, including TNF-alpha and IL-1 beta, as well as enzymes like COX-2, is believed to underlie its anti-inflammatory action. Additionally, ginger constituents such as shogaols and gingerols exhibit both antioxidant and anti-inflammatory activities, which may offer protection against oxidative stress and inflammation within the digestive tract[38], [62].

Ginger promotes the secretion of mucus, creating a protective layer in the stomach, and boosts the activity of antioxidant enzymes, helping to counteract oxidative stress. Additionally, ginger has been shown to inhibit the growth of *H. pylori*, a major contributor to stomach ulcers, potentially aiding in the elimination of the infection. Research has demonstrated that ginger extract can suppress COX-2 and NF- κ B activity, along with reducing the production of IL-1 β , IL-6, IL-8, and TNF- α in LPS-stimulated human peripheral blood mononuclear cells [63]. Further studies have found that ginger and its active components inhibit prostaglandin production by blocking COX-1 and COX-2, as well as leukotriene synthesis by inhibiting 5-

LOX [64]. Moreover, ginger has been shown to reduce NF- κ B expression and decrease levels of pro-inflammatory cytokines, such as TNF- α , IL-1 β , IL-6, and interferon- γ [65]. Ginger's ability to regulate gastric motility and enhance gastric emptying may also explain the observed reductions in symptom severity and frequency. In vivo experiments have indicated that hydromethanolic extracts of dried ginger effectively counteract spasmogenic effects [66].

Furthermore, research has indicated that ginger's calcium-antagonistic properties contribute to its spasmolytic effects. Enhanced spasmolytic activity helps protect the stomach from injury and ulcer formation by minimizing the exposure time of the mucosa to acidic gastric contents and accelerating gastric emptying. Ginger also stimulates the production and secretion of mucin, which acts as a protective buffer against the damaging effects of hydrochloric acid, particularly at the pyloric end of the stomach. Collectively, these findings suggest that ginger exerts gastroprotective effects by activating muscarinic receptors and inhibiting 5-HT₃ receptors [67]. Although the exact mechanisms of ginger's action and its potential long-term side effects in the management of functional dyspepsia require further investigation, our study contributes to the expanding evidence supporting its role as a complementary treatment for this disorder. These findings may hold significant implications for clinical practice

Regarding clinical implications, the findings of this study demonstrate the potential of ginger as a functional food component in the management of functional dyspepsia. Improvements in NDI scores, particularly in the domains of eating and drinking behaviors, indicate that ginger supplementation may help patients with FD overcome appetite loss and food avoidance associated with gastrointestinal discomfort. From a clinical nutrition perspective, integrating ginger into dietary interventions provides a natural, safe, and low-cost approach to complement conventional therapies. Nutritionists and dietitians are encouraged to consider ginger as part of comprehensive management plans aimed at reducing gastrointestinal symptoms and enhancing

patients' quality of life. However, to fully confirm its efficacy and determine appropriate dosing, further large-scale randomized controlled trials are warranted.

5.2 Effects of ginger on Fat Loss and anthropometric Parameters among FD patients

Contrary to expectations from previous metabolic studies on ginger, this study found no statistically significant changes in body fat percentage, BMI, or other anthropometric measurements after 8 weeks of supplementation. While there was a slight reduction in body fat percentage (from 26.8% to 25.9%, $p = 0.173$) and body fat mass (from 27.6 kg to 27.01 kg, $p = 0.324$), these changes were not meaningful from a clinical or statistical standpoint. Although earlier studies have highlighted ginger's thermogenic effects and its role in promoting lipid metabolism and fat loss [38,68], our study did not find a significant decrease in body fat following an eight-week intervention. The average baseline body fat percentage (26.8 ± 3.4) remained largely unchanged after supplementation (25.9 ± 3.1 , $p = 0.173$). These findings align with other research that has reported mixed results regarding ginger's anti-obesity and lipid-lowering properties [51,52,69]. The absence of notable fat reduction among FD patients could be attributed to several complex factors. One possibility is the relatively short duration of the intervention and the modest ginger dosage used, which may not have been sufficient to produce meaningful changes in body composition. Additionally, while ginger's thermogenic and lipid-lowering effects appear promising [40,41,70,71]. They may be comparatively mild relative to other metabolic boosters and therefore insufficient to achieve significant fat loss in an FD population. Ginger's thermogenic impact might simply be too modest to bring about noticeable changes in body fat among these patients.

Another possible explanation could be FD's complex and multifactorial nature, which involves altered gastrointestinal motility, visceral hypersensitivity, and psychological stress[72]. Since ginger primarily supports digestion, it may not fully address all these underlying mechanisms.

As a result, any improvement in symptoms may be limited, preventing broader benefits such as enhanced dietary habits and physical activity, which could influence body fat levels. Moreover, the interaction between appetite regulation and FD symptoms might also reduce the effectiveness of ginger in promoting fat loss. FD patients often suffer from irregular appetites due to issues like early satiety, nausea, and bloating. Although ginger may promote satiety [41], [73], this could unintentionally disrupt eating patterns. If ginger suppresses appetite without adequately relieving symptoms like nausea or bloating, it could lead to reduced food intake, insufficient nutrient consumption, and metabolic slowdown, ultimately counteracting any potential fat reduction.

5.3. Subgroup Comparisons

This study explored the effects of dietary ginger supplementation on body composition in patients with FD, with additional subgroup analyses by sex, age, and BMI category. While modest reductions in body fat percentage and fat mass were observed after 8 weeks, these changes were not statistically significant across the overall sample or within subgroups. The subgroup results suggest that short-term ginger supplementation at a daily dose of 1.08 grams does not significantly impact BMI, body fat, or WHR in patients with FD. These findings align with previous research indicating inconsistent or limited effects of ginger on anthropometric measures, especially in the absence of additional dietary or lifestyle interventions [7].

5.3.1. Influence of Sex

Although women had higher baseline body fat levels, the reduction in BF% was similar between sexes. This indicates that the response to ginger was independent of sex in this population. These results are consistent with prior studies reporting non-sex-specific effects of ginger on metabolic and inflammatory markers.

5.3.2. Influence of Age

Participants under 50 years showed slightly greater reductions in BF%, which may reflect better metabolic responsiveness. However, the differences were not statistically significant, and the limited sample size may reduce power to detect such effects.

5.3.3 Influence of BMI

Participants with higher baseline BMI (≥ 25 kg/m²) showed slightly greater improvements in BF% and fat mass, although the differences did not reach statistical significance. This suggests a possible trend where overweight or obese individuals may derive more benefit in terms of fat reduction. These observations are in line with studies indicating that individuals with higher adiposity may be more responsive to anti-inflammatory or thermogenic properties of ginger [69].

5.4. Clinical Implications

Although negative outcomes may seem disappointing, they offer valuable insights into the potential limitations of ginger as a therapeutic tool for body fat loss management among FD patients. These findings suggest that ginger's primary benefits are more symptom-targeted, offering relief from FD symptoms rather than exerting significant metabolic or weight-related effects. This underscores the potential need for a combined approach to FD management, integrating ginger with lifestyle interventions such as balanced nutrition, regular exercise, and stress management, for those facing body composition challenges. Moreover, the results emphasize the importance of refining future research designs by incorporating varied dosages, extended intervention periods, adjunctive treatments, and rigorous methodologies (e.g., randomized, double-blind trials) to better assess efficacy and underlying mechanisms. Finally, the lack of fat reduction calls for a reassessment of the assumed metabolic roles of ginger,

encouraging further investigation into its effects on biochemical markers like lipid profiles, insulin sensitivity, and inflammatory processes in FD patients.

5.5. Safety and Tolerability

Ginger supplementation was well tolerated, with no serious adverse events reported. A small number of participants experienced mild gastrointestinal discomfort, which was transient and did not lead to study withdrawal. These findings reaffirm ginger's strong safety profile, aligning with prior research. Mild bloating was reported by 14.9% of participants, which is comparable to outcomes from other clinical studies, for instance, a randomized controlled trial found a 12% incidence of bloating during ginger use [6]. This effect is likely linked to ginger's prokinetic properties, which can temporarily disturb gastric motility in sensitive individuals. Similar rates have been observed in past studies, such as one by [19], which also emphasized the benign and short-lived nature of this symptom.

Heartburn was reported by 12.8% of participants, echoing previous research findings. This side effect may stem from ginger's stimulation of gastric acid secretion, driven by compounds like gingerols and shogaols, which can irritate the stomach lining and worsen reflux. Lete and Allué noted that 10–15% of participants experienced heartburn at doses above 1 gram per day, indicating a dose-dependent relationship [32]. A systematic review also identified heartburn as a frequent, dose-related adverse effect [67]. Additionally, ginger's ability to relax the lower esophageal sphincter may contribute to reflux symptoms. However, some evidence suggests that mild heartburn could reflect beneficial changes in gut microbiota [68].

Diarrhea occurred in 10.6% of participants, a rate consistent with earlier studies but still lower than the side effect rates associated with synthetic prokinetic agents. Zeng et al. observed a similar frequency of diarrhea with high-dose ginger intake (2 grams/day) [69]. Other studies

have noted ginger's mild laxative properties as a manageable effect, with individual sensitivity and preparation method potentially influencing its occurrence [70].

The majority (87.2%) of participants rated ginger supplementation as good or excellent. This aligns with earlier findings showing over 85% of users reporting favorable tolerability despite occasional mild side effects [67]. Lete and Allué [39], similarly documented high satisfaction rates in their study on ginger for digestive issues. Importantly, no participants rated tolerability as poor or very poor in this study, underscoring its general acceptability. Supporting evidence from additional clinical trials [6, 19] also reported no instances of poor tolerability and found that ginger was often better tolerated than conventional drugs, reinforcing its role as a gentle, natural nutritional therapeutic option.

The findings highlight the potential of dietary ginger as a safe and effective option for managing FD, with significant implications for clinical practice. Clinically, they support the use of ginger as a natural, low-cost alternative or adjunct to conventional therapies for functional dyspepsia, particularly for patients seeking complementary treatment options. The high tolerability and safety of ginger may improve patient adherence and satisfaction with treatment regimens. From a research perspective, these results pave the way for further investigations to confirm the benefits in larger and more diverse populations, optimize dosage, and evaluate long-term safety and efficacy. Public health efforts could leverage ginger's accessibility to improve functional dyspepsia management, especially in resource-limited settings where access to conventional medications may be constrained.

5.6 Strengths and limitations of the study

Strengths: The study presents several notable strengths: Firstly, its clinical relevance stands out, as it addresses functional dyspepsia, a prevalent and burdensome gastrointestinal disorder

through a practical and accessible dietary intervention. This aligns well with current trends emphasizing nutritional approaches in medical management. A second strength lies in the standardized dosage used: participants received a commercially available ginger capsule at 1080 mg/day. This ensures consistency and reproducibility, enhancing the applicability of the findings to real-world settings. Furthermore, the study employed the Nepean Dyspepsia Index (NDI), a validated and disease-specific tool, which allowed for comprehensive and accurate assessment of both symptom changes and quality of life. The research also took a holistic approach, evaluating not only symptom severity and QoL but also anthropometric measures and adverse effects. This multi-dimensional analysis offers a broader understanding of ginger's potential impact. Importantly, the intervention demonstrated good tolerability, with no dropouts due to adverse effects, indicating that ginger supplementation is both safe and feasible in clinical and community environments.

Limitations: Despite these strengths, the study has some limitations. The open-label design means that neither participants nor investigators were blinded, which may have introduced placebo effects and observer bias, influencing subjective outcomes. Additionally, the absence of a control or placebo group limits the ability to attribute observed effects specifically to ginger, as other variables, such as diet, psychological state, or the natural fluctuation of symptoms, could have played a role. The relatively short intervention period of eight weeks may not be sufficient to assess long-term efficacy or the development of side effects. Generalizability is another concern, as the specific sample size and study setting may not reflect broader or more diverse populations. Furthermore, although symptom relief was evident, there were no significant changes in anthropometric measures like body weight or fat mass, which may reduce the relevance of ginger for individuals seeking metabolic benefits.

6. CONCLUSION AND FUTURE DIRECTIONS

This study provides evidence that dietary ginger supplementation may alleviate symptoms of functional dyspepsia (FD) while enhancing patients' quality of life. The intervention demonstrated good tolerability and was associated with minimal adverse effects, underscoring ginger's potential as a safe, natural nutritional therapeutic option. Although no significant changes were observed in anthropometric measures, like fat loss, the noticeable relief of gastrointestinal symptoms suggests improved digestive efficiency and possibly better nutrient assimilation. These findings highlight ginger's potential as a natural, nutrition-based supportive therapy in the management of FD.

Future Research Directions

To further elucidate the therapeutic potential of ginger, future studies should investigate its broader impacts on nutritional status, metabolic health, and gastrointestinal function. A well-designed randomized, double-blind, placebo-controlled trial (RCT) is essential to minimize bias and accurately determine the efficacy of ginger supplementation, with blinding helping to control for placebo effects.

An adequate sample size should be recruited to ensure statistical power, and the intervention period extended to 12–24 weeks to assess sustained benefits, long-term safety, and delayed outcomes, including improvements in quality of life.

Population stratification based on functional dyspepsia (FD) subtype (postprandial distress syndrome vs. epigastric pain syndrome), BMI category (normal vs. overweight/obese), and sex would allow for the examination of subgroup-specific responses and enhance the generalizability of findings.

Furthermore, the inclusion of both subjective outcome measures (validated symptom severity and quality-of-life scales) and objective biochemical markers; such as CRP, IL-6, TNF- α , fasting insulin, lipid profiles, and gut hormones (e.g., ghrelin and leptin) is recommended to explore the underlying mechanistic pathways of ginger's action on metabolic and gastrointestinal health.

7. SUMMARY

Background: Functional dyspepsia (FD) is a chronic gastrointestinal disorder characterized by upper abdominal discomfort, early satiety, postprandial fullness, and bloating, which significantly affects the quality of life of individuals and poses a global health burden. While pharmacological treatments such as proton pump inhibitors, prokinetics, and antidepressants are commonly used, they often provide only partial or temporary relief, leading many patients to seek complementary or alternative therapies. Ginger (*Zingiber officinale*), a widely used culinary and medicinal herb, has attracted attention for its potential digestive, anti-inflammatory, and prokinetic properties due to its active constituents, including gingerols and shogaols. In light of these properties, this study aimed to evaluate the effects of dietary ginger supplementation on dyspeptic symptoms, quality of life, and body composition among patients with functional dyspepsia, while also assessing its safety and tolerability.

Methods: An open-label clinical trial was conducted over an 8-week period involving adult patients diagnosed with functional dyspepsia who received ginger capsules at a dose of 540 mg twice daily (totaling 1080 mg/day). The primary outcomes were changes in dyspeptic symptoms and quality of life, assessed using the validated Nepean Dyspepsia Index (NDI), which captures symptom severity and their impact on daily function. Secondary outcomes included changes in anthropometric and body composition parameters such as body mass index (BMI), body fat percentage, and waist-to-hip ratio (WHR), measured using the IN-Body 720 Body Composition Analyzer, which employs bioelectrical impedance analysis (BIA). Self-reported side effects and tolerability ratings were collected at follow-up to evaluate the safety of the intervention.

Results: Ginger supplementation led to a statistically significant reduction in dyspeptic symptoms, with the total NDI score decreasing from a baseline mean of 19.07 ± 23.2 to

9.10 ± 19.3 after 8 weeks ($p < 0.05$). Improvements were also observed in NDI subdomains, including eating and drinking comfort, reduced interference with daily activities, and enhanced work performance. However, there were no statistically significant changes in body fat percentage, BMI, or overall body weight, indicating that ginger did not produce measurable effects on body composition during the intervention period. Mild and transient side effects such as bloating (14.9%), heartburn (12.8%), and diarrhea (10.6%) were reported, but no participants discontinued the study due to adverse effects. Overall, 87.2% of participants rated the intervention as either good or excellent in terms of tolerability.

Practical Implication: The findings from this study have several important practical implications for both clinical practice and public health nutrition. First and foremost, ginger supplementation at a dose of 1080 mg/day offers a safe, natural, and effective alternative adjunct to conventional pharmacological treatments for functional dyspepsia. Given the chronic and often recurrent nature of FD, and the limitations and side effects associated with long-term medication use, ginger provides a non-pharmacological strategy that is accessible, affordable, and culturally acceptable across many populations.

Ginger's impact on symptom relief and quality of life, despite not affecting body composition, is particularly valuable for patients whose main concern is functional discomfort rather than weight-related outcomes. This makes ginger a viable option for symptom management in clinical settings, especially in cases where traditional drug therapies are not well-tolerated or are contraindicated. In the context of integrative and functional medicine, ginger can be positioned as a functional food with therapeutic potential. Its incorporation into dietary counseling or personalized nutrition plans may support a more holistic approach to gastrointestinal health. Furthermore, as an over-the-counter supplement, ginger can be recommended by healthcare professionals including dietitians, gastroenterologists, and general practitioners, enabling patient-centered care and self-management.

In resource-limited settings, where access to specialized medical care or prescription medications may be constrained, ginger represents a low-cost intervention with meaningful clinical benefits. Its widespread availability and long history of traditional use enhance its feasibility for community-based and primary care programs aimed at managing chronic gastrointestinal conditions. Moreover, the high level of patient adherence and satisfaction reported in this study underscores ginger's acceptability and ease of integration into daily routines, which is a critical factor for long-term compliance in dietary interventions. Given its favorable safety profile, ginger could also be incorporated into public health recommendations or guidelines on managing common gastrointestinal complaints through diet-based strategies.

Overall, these findings support the broader integration of evidence-based nutraceuticals like ginger into the management of functional dyspepsia and potentially other chronic gastrointestinal disorders. As nutrition continues to play a growing role in preventative and therapeutic health strategies, interventions such as ginger supplementation can contribute significantly to personalized, sustainable, and non-invasive healthcare solutions.

Conclusion and Future directions: This study demonstrated that daily supplementation with ginger capsules at a dose of 1080 mg (540 mg twice daily) over an 8-week period significantly reduced dyspeptic symptoms and improved quality of life in patients with functional dyspepsia. Although there were no significant changes in body composition parameters such as body fat percentage, BMI, or weight, the intervention was safe, well-tolerated, and associated with high patient satisfaction. These findings support the use of ginger as a promising complementary dietary intervention for managing functional dyspepsia, particularly for patients seeking non-pharmacological options.

To strengthen the clinical evidence and confirm these findings, future studies should include randomized, double-blind, placebo-controlled trials to eliminate potential bias and establish a

causal relationship between ginger supplementation and symptom improvement. Longer-duration studies are also recommended to assess sustained benefits and potential delayed effects on body composition. Dose-response research will help determine the optimal therapeutic dosage for different patient populations. Mechanistic studies are needed to explore how ginger influences gastric motility, gut-brain interactions, and inflammatory pathways. Additionally, future research should include more diverse parts of populations, such as male, female, the elderly, and individuals with comorbid conditions, to improve generalizability. Finally, evaluating the synergistic potential of ginger when combined with other dietary or lifestyle interventions could further enhance its role in integrative gastrointestinal care.

8. KEYWORDS

Functional Dyspepsia, Ginger Supplementation, Nepean Dyspepsia Index (NDI), Quality of Life, Dietary Intervention, Nutraceuticals, Gastrointestinal Health, Herbal Therapy, Body Composition, Capsule Formulation, Anthropometric Measures, Complementary Medicine, Clinical Nutrition, Digestive Disorders, Tolerability

9. FUNDING

This work was supported by the Stipendium Hungaricum Scholarship Program of the Tempus Public Foundation (TPF) of the European Union under the European Regional Development Fund with the Registry number: SHE-26368-004/2019 to Lemlem Gebremariam Aregawi.

H-1077 Budapest, Kéthly Anna tér 1. Postal address: H-1438 Budapest 70, PO Box. 508.

Phone: (+36 1) 237-1300 Infoline: (+36 1) 237-1320, E-Mail:

stipendiumhungaricum@tpf.hu

10. ACKNOWLEDGMENTS

First and foremost, I would like to express my deepest gratitude to Dr. Csiki Zoltan, my supervisor, for his invaluable guidance, continuous support, and encouragement throughout my PhD journey. His expertise, mentorship, patience, and insightful feedback were instrumental in shaping this dissertation and my PhD academic success.

I also would like to extend my heartfelt appreciation to all the study participants whose willingness and cooperation made this research possible. Without their cooperation, this study would not have been possible. I am also sincerely thankful to the staff of the University of Debrecen, Internal Medicine Department III, the laboratory staff, and the medical students who supported me immensely during data collection and body composition measurements. I also extend my sincere thanks to the Doctoral School of Nutrition and Food Sciences: to the head of the school, the professors, lecturers, all administrative staff, and Secretaries especially Andrea, Aniko, and Judit, whose kind assistance and support made my academic experience smoother and easier.

I am also profoundly grateful to the University of Debrecen and Tempus Public Foundation for awarding me the Stipendium Hungaricum Scholarship, which provided the opportunity and means to pursue this academic dream and turn it into a reality.

To my beloved husband, Dr. Desta Tukue, thank you for your unwavering support, love, and understanding throughout my PhD journey. Your strength, patience, and belief in me made this achievement possible. You are the true embodiment of a devoted husband, one who boldly defied the stereotype that a woman's academic and professional aspirations must end once she becomes a wife and mother. In a developing world where many still believe that marriage and motherhood mark the end of a woman's educational journey, you stood firm and proved

otherwise. You not only encouraged me to pursue my dreams but also carried our shared responsibilities with grace, allowing me to fully commit to this path. This accomplishment is as much yours as it is mine. May God bless you abundantly for being my strength in weakness, my encouragement in doubt, and my unwavering partner in every sense of the word.

To my wonderful children, thank you for your patience, love, and for being a constant source of motivation and joy. Your presence kept me grounded and inspired me to push forward, even during the most challenging moments.

I would also like to express my heartfelt gratitude to my mother-in-law, Letebrhan Gebremariam, for her unwavering support and dedication in taking care of my children during my PhD studies. Your patience and support made it possible for me to focus on my academic journey, and I will always be deeply thankful.

Last but not least, I am forever grateful to my beloved parents and siblings for their unconditional love, prayers, and continuous encouragement that have sustained me throughout this journey. To my dear father, Gebremariam Aregawi, and my beloved mother, your nurturing spirits, unwavering support, and boundless compassion have profoundly shaped my life. You are the foundation of who I am today. I am truly blessed to be your child, and I will always honor and love you both.

I am also thankful to the staff of Adigrat University for their courage and support.

Above all, I thank God for His grace, guidance, and blessings throughout every step of my journey.

11. REFERENCES

- [1] M. D. D. Nicholas J. Talley, M.D., and Alexander C. Ford, “Functional Dyspepsia,” *new Engl. J. of Med.*, vol. 373, pp. 1853–1863, 2015, doi: 10.1056/NEJMra1501505.
- [2] H. Yamawaki, S. Futagami, M. Wakabayashi, and N. Sakasegawa, “Management of functional dyspepsia : state of the art and emerging therapies,” *Ther. Adv. Chronic Dis. Rev.*, vol. 9, no. 1, pp. 23–32, 2018, doi: 10.1177/https.
- [3] V. Stanghellini *et al.*, “Gastroduodenal Disorders,” *Gastroenterology*, vol. 150, no. 6, pp. 1380–1392, 2016, doi: 10.1053/j.gastro.2016.02.011.
- [4] P. Mi, Y. Yuan, P. Bercik, and P. Moayyedi, “Proton pump inhibitors for functional dyspepsia (Review),” *Cochrane Libr.*, no. 3, 2017, doi: 10.1002/14651858.CD011194.pub2.www.cochranelibrary.com.
- [5] M. L. Hu *et al.*, “Effect of ginger on gastric motility and symptoms of functional dyspepsia,” *World J. Gastroenterol.*, vol. 17, no. 1, pp. 105–110, 2011, doi: 10.3748/wjg.v17.i1.105.
- [6] K. S. Anh NH, Kim SJ, Long NP, Min JE, Yoon YC, Lee EG, Kim M, Kim TJ, Yang YY, Son EY, Yoon SJ, Diem NC, Kim HM, “Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials,” *Nutrients*, vol. 12, no. 1, p. 157, 2020.
- [7] N. Maharlouei *et al.*, “The effects of ginger intake on weight loss and metabolic profiles among overweight and obese subjects : A systematic review and meta-analysis of randomized controlled trials,” *Taylor Fr. Fr.*, vol. 8398, 2018, doi: 10.1080/10408398.2018.1427044.
- [8] J. A. N. Tack, N. J. Talley, M. Camilleri, G. Holtmann, and P. Hu, “Functional

- Gastroduodenal Disorders,” *Gastroenterology*, pp. 1466–1479, 2006, doi: 10.1053/j.gastro.2005.11.059.
- [9] J. A. N. Tack, R. A. F. Bisschops, and G. Sarnelli, “Pathophysiology and Treatment of Functional Dyspepsia,” *Gastroenterology*, pp. 1239–1255, 2004, doi: 10.1053/j.gastro.2004.05.030.
- [10] B. E. Lacy *et al.*, “Bowel Disorders,” *Gastroenterology*, vol. 150, no. 6, pp. 1393-1407.e5, 2016, doi: 10.1053/j.gastro.2016.02.031.
- [11] A. C. Ford *et al.*, “American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome,” *Am. J. Gastroenterol.*, no. June, pp. 1–18, 2018, doi: 10.1038/s41395-018-0084-x.
- [12] H. P. Parkman, W. L. Hasler, and Robert S. Fisher, “American Gastroenterological Association Technical Review on the Diagnosis and Treatment of Gastroparesis,” *Gastroenterology*, pp. 1592–1622, 2004, doi: 10.1053/j.gastro.2004.09.055.
- [13] D. A. Drossman, “Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV,” *Gastroenterology*, vol. 150, no. 6, pp. 1262-1279.e2, 2016, doi: 10.1053/j.gastro.2016.02.032.
- [14] G. O. First, “Dyspepsia and the microbiome : time to focus on the small intestine,” *Gut*, vol. 0, no. 0, pp. 8–9, 2016, doi: 10.1136/gutjnl-2016-312574.
- [15] N. A. Koloski, B. A. Hons, N. J. Talley, D. Ph, and P. M. Boyce, “Epidemiology and Health Care Seeking in the Functional GI Disorders : A Population-Based Study,” *Am. J. Gastroenterol.*, vol. 97, no. 9, 2002.
- [16] L. J. Delgado-Aros, S., Locke, G. R., Camilleri, M., Talley, N. J., Fett, S., Zinsmeister, A. R., & Melton, “Obesity is associated with increased risk of gastrointestinal

- symptoms: a population-based study,” *Am. J. Gastroenterol.*, vol. 99, no. 9, pp. 1801–1806, 2004.
- [17] R. S. Sandler, “The Burden of Gastrointestinal and Liver Diseases , 2006,” *Am. J. Clin. Nutr.*, pp. 2128–2138, 2006, doi: 10.1111/j.1572-0241.2006.00723.x.
- [18] K. J. Lee, “Obesity and Functional Gastrointestinal Disorders,” *Korean J Gastroenterol*, vol. 59, no. 1, pp. 1–7, 2012.
- [19] S. P. Weisberg *et al.*, “Obesity is associated with macrophage accumulation in adipose tissue Find the latest version : Obesity is associated with macrophage accumulation,” *J. Clin. Invest.*, vol. 112, no. 12, pp. 1796–1808, 2003, doi: 10.1172/JCI200319246.Introduction.
- [20] B. E. Wisse, “The Inflammatory Syndrome : The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity,” *J Am Soc Nephrol*, no. 16, pp. 2792–2800, 2004, doi: 10.1097/01.ASN.0000141966.69934.21.
- [21] S. D. Aros *et al.*, “Effect of Gastric Volume or Emptying on Meal-Related Symptoms After Liquid Nutrients in Obesity : A Pharmacologic Study,” *Clin. Gastroenterol. Hepatol.*, vol. 3565, no. 05, pp. 997–1006, 2005.
- [22] M. Camilleri and V. Stanghellini, “Current management strategies and emerging treatments for functional dyspepsia,” *Nat. Publ. Gr.*, vol. 10, no. March, 2013, doi: 10.1038/nrgastro.2013.11.
- [23] R. Fass and J. J. Ofman, “Gastroesophageal Reflux Disease — Should We Adopt a New Conceptual Framework ?,” *Am. J. Gastroenterol.*, vol. 97, no. 8, 2002.
- [24] D. A. Drossman, J. Tack, A. C. Ford, E. Szigethy, H. Törnblom, and L. Van Oudenhove, “Neuromodulators for Functional Gastrointestinal Disorders,”

- Gastroenterology*, vol. 154, no. 4, pp. 1140-1171.e1, 2018, doi:
10.1053/j.gastro.2017.11.279.
- [25] E. E. and M. H. Pittler, “Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials,” *Br. J. Anaesth.*, vol. 84, no. 3, pp. 367–71, 2000.
- [26] B. H. Ali, G. Blunden, M. O. Tanira, and A. Nemmar, “Some phytochemical, pharmacological and toxicological properties of ginger (*Zingiber officinale* Roscoe): A review of recent research,” *Food Chem. Toxicol.*, vol. 46, no. 2, pp. 409–420, 2008, doi: 10.1016/j.fct.2007.09.085.
- [27] Q. Q. Mao *et al.*, “Bioactive compounds and bioactivities of ginger (*zingiber officinale* roscoe),” *Foods*, vol. 8, no. 6, pp. 1–21, 2019. doi: 10.3390/foods8060185.
- [28] Y. Shukla and M. Singh, “Cancer preventive properties of ginger : A brief review,” *Food Chem. Toxicol.*, vol. 45, pp. 683–690, 2007, doi: 10.1016/j.fct.2006.11.002.
- [29] Q. Q. Mao *et al.*, “Bioactive compounds and bioactivities of ginger (*zingiber officinale* roscoe),” *Foods*, vol. 8, no. 6, pp. 1–21, 2019, doi: 10.3390/foods8060185.
- [30] S. Chrubasik, M. H. Pittler, and B. D. Roufogalis, “*Zingiberis rhizoma*: A comprehensive review on the ginger effect and efficacy profiles,” *Phytomedicine*, vol. 12, no. 9, pp. 684–701, 2005, doi: 10.1016/j.phymed.2004.07.009.
- [31] K. N. Ravindran, P. N., & Babu, “Ginger: The Genus *Zingiber.*,” *CRC Press.*, 2005.
- [32] J. Han, Y. Park, and K. W. Lee, “Gingerenone A, a polyphenol present in ginger, suppresses obesity and adipose tissue inflammation in high-fat diet-fed mice Sujin,” *Mol Nutr Food Res.*, vol. 61, no. 10, 2018, doi:
10.1002/mnfr.201700139.Gingerenone.
- [33] S. M. Zick *et al.*, “Phase II study of the effects of ginger root extract on eicosanoids in

- colon mucosa in people at normal risk for colorectal cancer,” *Cancer Prev. Res.*, vol. 4, no. 11, pp. 1929–1937, 2011, doi: 10.1158/1940-6207.CAPR-11-0224.
- [34] W. Kl *et al.*, “Effects of ginger on gastric emptying and motility in healthy humans . PubMed Commons,” *Eur J Gastroenterol Hepatol*, vol. 20, no. 5, pp. 1–2, 2014.
- [35] K. L. Grant and R. B. Lutz, “Alternative Therapies: Ginger,” *Am. J. Heal. Pharm.*, vol. 57, no. 10, pp. 945–947, 2000.
- [36] F. Borrelli, R. Capasso, G. Aviello, M. H. Pittler, and A. A. Izzo, “Effectiveness and Safety of Ginger in the Treatment of Pregnancy-Induced Nausea and Vomiting,” *Women and Birth*, vol. 105, no. 4, pp. 849–856, 2005, doi: 10.1097/01.AOG.0000154890.47642.23.
- [37] S. Park and S. J. E. C. K. Ha, “The effects of steamed ginger ethanolic extract on weight and body fat loss : a randomized , double-blind , placebo-controlled clinical trial,” *Food Sci. Biotechnol.*, vol. 29, no. 2, pp. 265–273, 2020, doi: 10.1007/s10068-019-00649-x.
- [38] A. Giacosa *et al.*, “The Effect of Ginger (*Zingiber officinalis*) and Artichoke (*Cynara cardunculus*) Extract Supplementation on Functional Dyspepsia : A Randomised , Double-Blind , and Placebo-Controlled Clinical Trial,” *Hindawi*, 2015, doi: 10.1155/2015/915087.
- [39] I. Lete and J. Allué, “The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy,” *Integr. Med. Insights*, vol. 11, pp. 11–17, 2016, doi: 10.4137/IMIS36273.
- [40] S. Atashak, M. Peeri, M. A. Azarbayjani, S. R. Stannard, and M. M. Haghghi, “Obesity-related cardiovascular risk factors after long- term resistance training and

- ginger supplementation,” *J. Sport. Sci. Med.*, no. September, pp. 685–691, 2011.
- [41] A. Muhammad S. Mansour, Yu-Ming Ni, Amy L. Roberts, Michael Kelleman and R. M.-P. St-Onge, “hormonal parameters in overweight men : A pilot study,” *Metabolism*, vol. 61, no. 10, pp. 1347–1352, 2013, doi: 10.1016/j.metabol.2012.03.016.Ginger.
- [42] Z. M. Al-amin, M. Thomson, K. K. Al-qattan, R. Peltonen-shalaby, and M. Ali, “Anti-diabetic and hypolipidaemic properties of ginger (*Zingiber officinale*) in streptozotocin-induced diabetic rats,” *Br. J. Nutr. Br. J. Nutr. This J. doesn't have a profile Res. yet. Interest. this journal? Get Notif. when it Act. its profile, start Get. Updat. I'm Interest.*, pp. 660–666, 2006, doi: 10.1079/BJN20061849.
- [43] G.D.Eslick, “Gastrointestinal symptoms and obesity : a meta-analysis,” *Obes. Rev.*, no. May, pp. 469–479, 2012, doi: 10.1111/j.1467-789X.2011.00969.x.
- [44] L. G. Aregawi, M. Shokrolahi, T. G. Gebremeskel, and C. Zoltan, “The Effect of Ginger Supplementation on the Improvement of Dyspeptic Symptoms in Patients With Functional Dyspepsia,” *cureus*, vol. 15, no. 9, pp. 1–8, 2023, doi: 10.7759/cureus.46061.
- [45] M. Nikkhah, B. Iradj, and M. Azita, “Ginger in gastrointestinal disorders : A systematic review of clinical trials,” *Food Sci. Nutr.*, vol. 7, pp. 96–108, 2019, doi: 10.1002/fsn3.807.
- [46] N. S. Mashhadi, R. Ghiasvand, G. Askari, M. Hariri, and L. Darvishi, “Anti - Oxidative and Anti - Inflammatory Effects of Ginger in Health and Physical Activity : Review of Current Evidence,” *Int. J. Prev. Med.*, 2012.
- [47] H. Lien *et al.*, “Effects of ginger on motion sickness and gastric slow- wave dysrhythmias induced by circularvection,” *AJP Gastrointest. Liver Physi.*, vol. 0362,

- pp. 481–489, 2025.
- [48] M. B. Micklefield GH, Redeker Y, Meister V, Jung O, Greving I, “Effects of ginger on gastroduodenal motility.,” *Int J Clin Pharmacol Ther.* 1999 Jul;37(7)341-6., vol. 37, no. 7, pp. 341–6, 1999.
- [49] K. Platel, K. and Srinivasan, “Digestive Stimulant Action of Spices,” *Indian J. Med. Res.*, vol. 119, pp. 167–179, 2004.
- [50] K. Platel and K. Srinivasan, “Digestive stimulant action of spices : A myth or reality ?,” *Indian J Med Res.*, no. October, 2014.
- [51] S. Mahluji, V. E. Attari, M. Mobasseri, L. Payahoo, and A. Ostadrahimi, “Effects of ginger (*Zingiber officinale*) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients,” *Int J Food Sci Nutr*, vol. 7486, no. 6, pp. 682–686, 2013, doi: 10.3109/09637486.2013.775223.
- [52] F. Shidfar, A. Rajab, T. Rahideh, N. Khandouzi, S. Hosseini, and S. Shidfar, “The effect of ginger (*Zingiber officinale*) on glycemic markers in patients with type 2 diabetes,” *J Complement Integr Med*, vol. 12, no. 2, pp. 165–170, 2015, doi: 10.1515/jcim-2014-0021.
- [53] C. Roxb and I. Derivatives, “ α -Glucosidase and Pancreatic Lipase Inhibitory Activities of Diterpenes from Indian Mango Ginger (*Curcuma amada* Roxb.) and Its Derivatives,” *Molecules*, vol. 24, 2019.
- [54] M. G. Abolfathi Mohammad, Ebrahim Falahi, Barakatun-Nisak Mohd Yusof, Zubaidah Nor Hanipah, Mohd Redzwan Sabran, Loqman Mohamad Yusof, “The effects of the ginger supplements on inflammatory parameters in type 2 diabetes patients: A systematic review and meta-analysis of randomised controlled trials,” *Clin.*

Nutr. ESPEN, Vol. 46, 2021, Pages 66-72, vol. 46, pp. 66–72, 2021.

- [55] U. S. F. and D. A. I. S. for A. D. Products, “Ingredient Search for Approved Drug Products,” *U.S. FOOD DRUG Administration*, 2021.
- [56] B. White, “Ginger: An Overview,” *Am Fam Physician.*, pp. 7–9, 2007.
- [57] S. Nammi, S. Sreemantula, and B. D. Roufogalis, “Protective Effects of Ethanolic Extract of *Zingiber officinale* Rhizome on the Development of Metabolic Syndrome in High-Fat Diet-Fed Rats,” *Basic Clin. Pharmacol. Toxicol.*, pp. 366–373, 2009, doi: 10.1111/j.1742-7843.2008.00362.x.
- [58] N. J. Talley, M. Verlinden, and M. Jones, “Quality of life in functional dyspepsia : responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form,” 2001.
- [59] N. J. Talley, D. Ph, M. Verlinden, D. Ph, M. Jones, and D. Ph, “Validity of a New Quality of Life Scale for Functional Dyspepsia : A United States Multicenter Trial of the Nepean Dyspepsia Index,” vol. 94, no. 9, 1999.
- [60] X. Tian *et al.*, “Translation and validation of the Nepean Dyspepsia Index for functional dyspepsia in China,” vol. 15, 2009, doi: 10.3748/wjg.15.3173.
- [61] S. Mahadeva, H. Wee, K. Goh, and J. Thumboo, “Quality of life in South East Asian patients who consult for dyspepsia : Validation of the short form Nepean Dyspepsia Index,” vol. 36, pp. 1–9, 2009, doi: 10.1186/1477-7525-7-45.
- [62] W. Marx *et al.*, “Ginger—Mechanism of action in chemotherapy-induced nausea and vomiting: A review,” *Crit. Rev. Food Sci. Nutr.*, vol. 57, no. 1, pp. 141–146, 2017, doi: 10.1080/10408398.2013.865590.
- [63] S. Shishodia, “Suppression of the Nuclear Factor-KB Activation Pathway by Spice-

- Derived Phytochemicals,” *Ann. N. Y. Acad. Sci.*, vol. 441, pp. 434–441, 2004, doi: 10.1196/annals.1329.054.
- [64] F. Aktan, S. Hennes, V. H. Tran, C. C. Duke, B. D. Roufogalis, and A. J. Ammit, “Gingerol metabolite and a synthetic analogue Capsarol™ inhibit macrophage NF-κB-mediated iNOS gene expression and enzyme activity,” *Planta Med.*, vol. 72, no. 8, pp. 727–734, 2006, doi: 10.1055/s-2006-931588.
- [65] E. Tjendraputra, V. H. Tran, D. Liu-Brennan, B. D. Roufogalis, and C. C. Duke, “Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells,” *Bioorg. Chem.*, vol. 29, no. 3, pp. 156–163, 2001, doi: 10.1006/bioo.2001.1208.
- [66] K. Gaus, Y. Huang, D. A. Israel, S. L. Pendland, B. A. Adeniyi, and G. B. Mahady, “Standardized ginger (*Zingiber officinale*) extract reduces bacterial load and suppresses acute and chronic inflammation in Mongolian gerbils infected with cagA + *Helicobacter pylori*,” *Pharm. Biol.*, vol. 47, no. 1, pp. 92–98, 2009, doi: 10.1080/13880200802448690.
- [67] W. Y. Chung, Y. J. Jung, Y. J. Surh, S. S. Lee, and K. K. Park, “Antioxidative and antitumor promoting effects of [6]-paradol and its homologs,” in *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, 2001, vol. 496, no. 1–2, pp. 199–206. doi: 10.1016/S1383-5718(01)00221-2.
- [68] Y. Li, V. H. Tran, C. C. Duke, and B. D. Roufogalis, “Preventive and Protective Properties of *Zingiber officinale* (Ginger) in Diabetes Mellitus , Diabetic Complications , and Associated Lipid and Other Metabolic Disorders : A Brief Review,” *Evidence-Based Complement. Altern. Med.*, vol. 2012, 2012, doi: 10.1155/2012/516870.

- [69] V. E. Attari, A. Ostadrahimi, M. A. Jafarabadi, S. Mehralizadeh, and S. Mahluji, "Changes of serum adipocytokines and body weight following *Zingiber officinale* supplementation in obese women : a," *Eur. J. Nutr.*, vol. 55, no. 6, pp. 2129–2136, 2016, doi: 10.1007/s00394-015-1027-6.
- [70] K. Sugimoto, H. Takeuchi, K. Nakagawa, and Y. Matsuoka, "Hyperthermic Effect of Ginger (*Zingiber officinale*) Extract-Containing Beverage on Peripheral Skin Surface Temperature in Women," *Hindawi Evidence-Based Complement. Altern. Med.*, vol. 2018, 2018, doi: 10.1155/2018/3207623.
- [71] Y. Iwasaki *et al.*, "A nonpungent component of steamed ginger —[10] -shogaol — increases adrenaline secretion via the activation of TRPV1," *Nutr. Neurosci.*, vol. 8305, 2013, doi: 10.1080/110284150600955164.
- [72] M. M. Walker, M. D. Potter, and N. J. Talley, "Best Practice & Research Clinical Gastroenterology Tangible pathologies in functional dyspepsia," *Best Pract. Res. Clin. Gastroenterol.*, vol. 40–41, p. 101650, 2019, doi: 10.1016/j.bpg.2019.101650.
- [73] V. Ebrahimzadeh, A. Mohammad, A. Jafarabadi, and M. Zemestani, "Effect of *Zingiber officinale* Supplementation on Obesity Management with Respect to the Uncoupling Protein 1 -3826A > G and β 3-adrenergic Receptor Trp64Arg Polymorphism," *phytother. Res.*, no. February, 2015.

12.APPENDIX

12.1 Appendix: Study Questionnaires

Topic: The Effect of Ginger on Functional Dyspepsia Symptoms and Body Fat Content Among Patients with Functional Dyspepsia: An Academic Study from the University of Debrecen (PhD Study)

PROTOCOL:

PATIENT'S No. :

PATIENT'S INITIALS:

Date of birth:

Date of completion:

Principal Investigator: Lemlem Gebremariam Aregawi (PhD student)
Supervisor: Dr. Csiki Zoltan

Study Site: University of Debrecen

Inclusion criteria

1. Patients suffering from PDS as per Rome IV. See Questionnaire in annex 1
 Yes No
2. Patients aged between 18 and 72 years inclusive.
 Yes No
3. Male or female patients.
 Yes No
4. Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.
 Yes No

Exclusion criteria

1. Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for entry into the study.
 Yes No
2. Patients with an active major psychiatric condition (depression, anxiety disorder, alcohol or substance abuse). Patients taking a stable dose of a single antidepressant (with the exception of amitryptiline) during the last 3 months are eligible.
 Yes No
3. Patients suffering from diabetes type 1 or type 2.
 Yes No
4. Patients taking prohibited medications* during the last 2 weeks prior to screening. A wash-out is allowed if medically indicated (lack of efficacy or side-effects). This wash-out is minimum two weeks for PPIs.
 Yes No
5. Patients with confirmed gastro-intestinal organic disease.
 Yes No
6. Patients with former digestive surgery affecting upper gut motility.
 Yes No
7. Patients affected by extradigestive disease responsible for digestive symptoms.
 Yes No
8. Patients with predominant irritable bowel syndrome (IBS) and/or reflux disease (GERD). (See Annex 2.: three “yes” are relevant for the diagnosis of GERD.)
 Yes No
9. Patients with predominant symptoms of Epigastric Pain Syndrome several times a week.
 Yes No
10. Patients with daily symptoms of Chronic Idiopathic Nausea.
 Yes No
11. Patients with daily symptoms of Excessive Belching.
 Yes No
12. Patients with vomiting more than one day a month.
 Yes No

Prohibited medications*

1. **Inhibitors/ neutralisers of gastric acid secretion:** Antacids, Anti-H2; Proton pump inhibitors (A wash-out of 14 days is feasible).

2. **Modifiers of Gut motility**

Macrolides

Dopamine Antagonists: Metoclopramide, Domperidone, Clebopride, Levosulpride, Tiapride. Domperidone and metoclopramide allowed during follow-up if symptoms are relapsing

Serotonin Agonists/Antagonists: Ondansetron, Granisetron, Prucalopride, Sumatriptan, Rizatriptan, Nazatriptan, Eletriptan, Zomitriptan.

Not allowed when chronically taken more than once a week

Miscellaneous

Organonitrates, Clonidine

These drugs are allowed if single up to stable dose more than 3 month prior to screening.

3. **Modifiers of gut perception**

Opioids (Morfine and derivates)

Paracetamol associated with codein, tramadol and other major pain killers

4. **NSAIDs (Inducers of gastric lesions)**

Acetylsalicylic acid, Diclofenac, Ibuprofen, Indomethacin, Metamizol, Naproxene, Peroxicam, Celecoxib (prophylactic aspirin doses of up to 500 mg/d are allowed)

5. **Medications for neuro-psychiatric disorders**


Neuroleptics: Phenothiazines, thioxathenes, butyrophenones, diphenylpiperidines, and derivates: e.g.:Chlorpromazine, Fluphenazine, Thiorisazine, Loxapine, Clozapine, Haloperidol, (one medication as sleep pill at night is allowed).

6. weight-loss/gain medications or supplements

1. Fejezet LPDS kérdőív (a beteg egyedül tölti ki)

1. rész.: Hol van a gyomor?

A gyomor az alább leírt területen helyezkedik el (a köldök és a szegycsont – mellcsont vége között).



2. Rész. Általános kérdések az Ön gyomor tüneteiről

a. Gyakran érez-e kellemetlen érzést vagy szenved kényelmetlenségtől a gyomor területén?

Igen

Nem

b. Ha „igen”, akkor ezt a kellemetlen érzést ételek fogyasztása váltja-e ki vagy súlyosbítja?

Igen

Nem

3. Rész.: Az Ön tüneteire vonatkozó részletes kérdések (orvos jelenléte nélkül)

1. Mennyire nehéz volt a mai napon Önnek befejeznie egy szokásos (normális) étkezést mivel túl hamar érezte jóllakottnak magát?



2. Mennyire súlyos volt a mai napon az az érzése, hogy „az étel megnyomta a gyomrát”?



3. Mennyire szenvedett Ön a mai napon gyomortáji puffadástól?



4. Mennyire szenvedett Ön a mai napon gyomortáji fájdalomtól?



5. Mennyire szenvedett Ön a mai napon gyomortáji égő érzéstől?



6. Mennyire szenvedett Ön a mai napon émelygéstől, hányingertől?



7. Mennyire szenvedett Ön a mai napon nehéz böfögésérzéstől?



8. Mennyire szenvedett Ön a mai napon szegycsont (mellcsont) mögötti (a mellkasban levő) égő érzéstől?



2. Fejezet LPDS kérdőív (a beteg az orvos jelenlétében tölti ki) -

Fogja az Ön által kitöltött kérdőívet és menjen kezelőorvosához, majd orvosa jelenlétében töltsse ki az alábbi részt

1. Mennyire nehéz volt a mai napon Önnek befejeznie egy szokásos (normális) étkezést mivel túl hamar érezte jóllakottnak magát?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

1a. Vannak a kérdésben olyan szavak melyeket nem ért?

1b. Írja le saját szavaival, amit megértett

1c. Mit jelent Önnek: „nehéz volt a mai napon befejezni egy szokásos (normális) étkezést mivel túl hamar érezte jóllakottnak magát”?

1d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

1e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

1f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt az Ön gyors jóllakottság érzése?

B – A mai napon milyen súlyos volt Önnek az az érzése, hogy túl gyorsan kellett befejeznie az étkezését?

C – A mai napon milyen súlyos volt az a gondja, hogy be kellett fejeznie étkezését mert túl korán lakott jól?

Megjegyzés (opcionális)

2. Mennyire súlyos volt a mai napon az az érzése, hogy „az étel megnyomta a gyomrát”?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

2a. Vannak a kérdésben olyan szavak melyeket nem ért?

2b. Írja le saját szavaival amit megértett

2c. Mit jelent Önnek: „a mai napon azt érezte, hogy az étel megnyomta a gyomrát”

2d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

2e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

2f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt az étkezést követő gyomor nehézség érzése?

B – A mai napon mennyire volt nehéz az emésztése?

C – A mai napon milyen súlyos volt az az érzése, hogy az étel túl sok ideig van a gyomrában?

Megjegyzés (opcionális)

3. Mennyire szenvedett Ön a mai napon gyomortáji puffadástól?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

3a. Vannak a kérdésben olyan szavak melyeket nem ért?

3b. Írja le saját szavaival amit megértett

3c. Mit jelent Önnek a „gyomortáji puffadás a mai napon”?

3d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

3e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

3f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt az Ön gyomortáji puffadásérzése?

B – A mai napon milyen súlyos volt a gyomorban érzett nyomásérzés?

C – A mai napon milyen súlyos volt az az érzése, hogy a gyomra megduzzadt?

Megjegyzés (opcionális)

4. Mennyire szenvedett Ön a mai napon gyomortáji fájdalomtól?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

4a. Vannak a kérdésben olyan szavak melyeket nem ért?

4b. Írja le saját szavaival amit megértett

4c. Mit jelent Önnek: „gyomortáji fájdalom”?

4d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

4e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

4f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt a gyomrában a fájdalomérzése?

B – A mai napon mennyire volt fájdalmas a gyomra?

C – A mai napon milyen súlyos volt a fájdalomérzés a gyomrában?

Megjegyzés (opcionális)

5. Mennyire szenvedett Ön a mai napon gyomortáji égő érzéstől?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

5a. Vannak a kérdésben olyan szavak melyeket nem ért?

5b. Írja le saját szavaival amit megértett

5c. Mit jelent Önnek „gyomortáji égő érzés”?

5d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

5e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

5f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt a gyomrában az égő érzése?

B – A mai napon mennyire égett a gyomra?

C – A mai napon milyen súlyos volt az égő érzés a gyomrában?

Megjegyzés (opcionális)

6. Mennyire szenvedett Ön a mai napon émelygéstől, hányingertől?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

6a. Vannak a kérdésben olyan szavak melyeket nem ért?

6b. Írja le saját szavaival amit megértett

6c. Mit jelent Önnek a hányinger?

6d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

6e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

6f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt a hányingere?

B – A mai napon mennyire súlyos volt az az érzése, hogy hánynia kell?

C – A mai napon milyen súlyos volt az émelygésézése?

Megjegyzés (opcionális)

7. Mennyire szenvedett Ön a mai napon nehéz böfögésérzéstől?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

7a. Vannak a kérdésben olyan szavak melyeket nem ért?

7b. Írja le saját szavaival amit megértett

7c. Mit jelent Önnek a „nehéz böfögés”?

7d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

7e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

7f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt az az érzése, hogy túlzottan böfögnie kell?

B – A mai napon mennyire súlyos volt a túlzott böfögésérzése?

C – A mai napon milyen súlyos volt a kellemetlen böfögése?

Megjegyzés (opcionális)

8. Mennyire szenvedett Ön a mai napon szegycsont (mellcsont) mögötti (a mellkasban levő) égő érzéstől?



Nincs tünet



Enyhe



Közepes



Súlyos



Nagyon súlyos

8a. Vannak a kérdésben olyan szavak melyeket nem ért?

8b. Írja le saját szavaival amit megértett

8c. Mit jelent Önnek: „égő érzés a szegycsont (mellcsont) mögött (a mellkasban)”?

8d. Mit gondol a javasolt válaszok választékáról? Hogyan választotta ki az Ön számára legmegfelelőbbet?

8e. Vissza tud-e pontosan emlékezni ennek a tünetnek a súlyosságára az utóbbi 24 órában?

8f. Feltehetjük kérdést másképpen is: melyik ennek a kérdésnek a legjobb megfogalmazása?

A – A mai napon milyen súlyos volt az az érzése, hogy a szegycsont (mellcsont) mögött (a mellkasában) égő érzés van?

B – A mai napon mennyire súlyos volt a gyomorégése (pyrosisa)?

C – A mai napon milyen súlyos volt a mellkasában a savas refluxérzése?


Megjegyzés (opcionális)

Aláírás:

Dátum:

4. Fejezet: Rajzok (a beteg az orvos jelenlétében tölti ki)

1. Normális étkezés elfogyasztásának nehézsége mert Ön túl gyorsan érezte jóllakottnak magát



1a. Jól mutatja-e afenti ábra azt az érzést, hogy Ön számára a normális étkezés elfogyasztása nehéz volt mert túl gyorsan érezte jóllakottnak magát?


1b. Írja le saját szavaival az ábra jelentését!

1c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

1d. Van-e javaslata egy teljesen más megközelítésre?

1e. Csak a rajz alapján felismerné-e a fenti tünetet?

2. Az érzés, hogy az étel megnyomta a gyomrát



2a. Leírja-e ez az ábra azt az érzést, hogy az étel megnyomta a gyomrát?


2b. Írja le saját szavaival az ábra jelentését!

2c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

2d. Van-e javaslata egy teljesen más megközelítésre?

2e. Csak a rajz alapján felismerné-e a fenti tünetet?

3. Fájdalomérzés a gyomorban



3a. Leírja-e ez az ábra a gyomorban levő fájdalomérzést?


3b. Írja le saját szavaival az ábra jelentését!

3c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

3d. Van-e javaslata egy teljesen más megközelítésre?

3e. Csak a rajz alapján felismerné-e a fenti tünetet?

4. Puffadásérzés a gyomorban



4a. Leírja-e ez az ábra a gyomorban levő puffadásérzést?


4b. Írja le saját szavaival az ábra jelentését!

4c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

4d. Van-e javaslata egy teljesen más megközelítésre?

4e. Csak a rajz alapján felismerné-e a fenti tünetet?

5. Gyomortáji égő érzés.



5a. Leírja-e ez az ábra a gyomorban levő égő érzést?


5b. Írja le saját szavaival az ábra jelentését!

5c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

5d. Van-e javaslata egy teljesen más megközelítésre?

5e. Csak a rajz alapján felismerné-e a fenti tünetet?

6. Hányinger (émelygés)




6a. Leírja-e ez az ábra a hányingert (émelygést)?

6b. Írja le saját szavaival az ábra jelentését!

6c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

7. Nehéz böfögés a mai napon



7a. Leírja-e ez az ábra a böfögési nehezítettséget?


7b. Írja le saját szavaival az ábra jelentését!

7c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

7d. Van-e javaslata egy teljesen más megközelítésre?

7e. Csak a rajz alapján felismerné-e a fenti tünetet?

8. Égő érzés a mellcsont mögött (az ön mellkasában)



8a. Leírja-e ez az ábra a a mellcsont mögött (az ön mellkasában) levő égő érzést?

8b. Írja le saját szavaival az ábra jelentését!

8c. Változtatna-e valamit a rajzon, hogy jobban jellemezze, érthetővé tegye a tünetet?

NDI QUESTIONNAIRE

1. Tension/anxiety 2. Interference with daily activity 3. Eating/drinking 4. Knowledge/control 5. Work/study

Patient Id _____

IC. signature _____ date _____

Tension (tension)	1.No		2 light		3,curre ntly		4, heavy		5, very heavy	
	bef ore	aft er	b	A	B	A	B	A	B	A
1. Are you experiencing emotional disturbances as a result of gastric complaints in the last 2 weeks?										
2. Are you sensitive, tense, or frustrated due to gastric complaints within 2 weeks final										
Restrictions on daily activities										
3. Is the ability for that activity fun (recreation, traveling, hobbies, sports and so on) are disturbed as a result of gastric complaints in the last 2 weeks?										
4. What is enjoyment in that activity fun (recreation, traveling, hobbies, sports and so on) are disturbed as a result gastric complaints in the last 2 weeks?										
Eating and drinking										
5. Is the ability to eat and drink disturbed due to internal stomach complaints Last 2 weeks?										
6.What is the pleasure in eating and drinking disturbed due to internal stomach complaints Last 2 weeks?										
Knowledge/control	1 almost not once		2.som etimes		3.Often		4.very often		5.always	

7. Do you think that you will always experience gastric complaints within 2 weeks final?									
8. Do you think that gastric complaints you are due to a very serious illness (cancer or heart) within 2 weeks final?									
Work/study	1.No	2.light	3. currentl y	4. heavy	5.very heavy				
9. What is your ability to work? or studies are interrupted by gastric complaints in the last 2 weeks?									
10. What is your pleasure at work or studies were interrupted by internal gastric complaints Last 2 weeks?									

QUESTIONNAIRE

For each question draw a circle around the number of the appropriate answer

PDS - Postprandial Distress Syndrome

1. In the last 3 months, how often did you feel uncomfortably full after a regular sized meal?
 0. Never
 1. Less than one day a month
 2. One day a month
 3. Two to three days a month
 4. One day a week
 5. More than one day a week
 6. Every day

2. Have you had this uncomfortable fullness after meals 6 months or longer?
 1. Yes
 2. No

3. In the last 3 months, how often were you unable to finish a regular size meal?
 0. Never
 1. Less than one day a month

2. One day a month
 3. Two to three days a month
 4. One day a week
 5. More than one day a week
 6. Every day
4. Have you had this inability to finish regular size meals 6 months or longer?
 1. Yes
 2. No
 5. How often did you suffer from upper abdominal bloating after meals during the last 3 months?
 1. Never
 2. One a month or less
 3. 2,3 times a month
 4. One a week
 5. Several times a week
 6. Every day

Nausea

6. In the last 3 months, how often did you have bothersome nausea?
 0. Never
 1. Less than one day a month
 2. One day a month
 3. Two to three days a month
 4. One day a week
 5. More than one day a week
 6. Every day
7. Did this nausea start more than 6 months ago?
 1. Yes
 2. No
8. How often does this nausea (The feeling that you can vomit) occur after meals?
 1. Never
 2. From time to time
 3. Sometimes
 4. Often
 5. Most of the time
 6. Permanently
9. How often does this nausea occur between the meals when the stomach is empty?
 1. Never
 2. From time to time
 3. Sometimes
 4. Often
 5. Most of the time
 6. Permanently

EPS - Epigastric Pain Syndrome

10. In the last 3 months, how often did you have pain or burning in the middle of your abdomen, above your belly button but not in your chest?
 0. Never
 1. Less than one day a month
 2. One day a month
 3. Two to three days a month
 4. One day a week
 5. More than one day a week
 6. Every day

11. Have you had this pain or burning 6 months or longer?
 1. Yes
 2. No

12. Did this pain or burning occur and then completely disappear during the same day?
 1. Yes
 2. No

13. Usually, how severe was the pain or burning in the middle of your abdomen, above your belly button?
 1. Very mild
 2. Mild
 3. Moderate
 4. Severe
 5. Very severe

14. How often do you suffer from upper abdominal pain after meals?
 1. Never
 2. From time to time
 3. Sometimes
 4. Often
 5. Most of the time
 6. Permanently

15. How often do you suffer from upper abdominal pain between the meals when the stomach is empty?
 1. Never
 2. From time to time
 3. Sometimes
 4. Often
 5. Most of the time
 6. Permanently

16. How often do you suffer from abdominal pain occurring in another place of the abdomen or behind the chest bone?
 1. Never
 2. From time to time

3. Sometimes
4. Often
5. Most of the time
6. Permanently

17. How often is this pain combined with a burning sensation in the upper abdomen?

1. Never
2. From time to time
3. sometimes
4. Often
5. Most of the time
6. Permanently

18. Did this pain or burning usually get better or stop after a bowel movement or passing gas?

1. Never or rarely
2. Sometimes
3. Often
4. Most of the time
5. Always

EB - Excessive Belching

19. In the last 3 months, how often did you experience bothersome belching?

0. Never
1. Less than one day a month
2. One day a month
3. Two to three days a month
4. One day a week
5. More than one day a week
6. Every day

20. Did this bothersome belching start more than 6 months ago?

1. Yes
2. No

13. LIST OF PUBLICATIONS



**UNIVERSITY of
DEBRECEN**

**UNIVERSITY AND NATIONAL LIBRARY
UNIVERSITY OF DEBRECEN**

H-4002 Egyetem tér 1, Debrecen
Phone: +3652/410-443, email: publikaciok@lib.unideb.hu

Registry number: DEENK/331/2025.PL
Subject: PhD Publication List

Candidate: Lemlem Gebremariam Aregawi
Doctoral School: Doctoral School of Nutrition and Food Sciences
MTMT ID: 10099904

List of publications related to the dissertation

- Aregawi, L. G.**, Csiki, Z.: Effects of ginger supplementation on quality of life in patients with functional dyspepsia: an open-label, clinical trial.
Advances in Integrative Medicine. [Epub ahead of print], 2025.
DOI: <http://dx.doi.org/10.1016/j.aimed.2025.100477>
IF: 1.2 (2023)
- Aregawi, L. G.**, Csiki, Z.: Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients with Functional Dyspepsia.
Curr. Ther. Res.-Clin. Exp. 102, 1-26, 2025.
DOI: <http://dx.doi.org/10.1016/j.curtheres.2025.100792>
IF: 1.6 (2023)

List of other publications

- Aregawi, L. G.**, Csiki, Z.: Ginger's nutritional implication on gastrointestinal health.
Clinical Nutrition Open Science. 61, 1-13, 2025.
DOI: <http://dx.doi.org/10.1016/j.nutos.2025.02.008>
- Aregawi, L. G.**, Gebremeskel, T. G., Csiki, Z.: Preventive and therapeutic effects of ginger on bowel disease: a review of clinical trials.
Pharmacological Research - Modern Chinese Medicine. 12, 1-8, 2024.
DOI: <http://dx.doi.org/10.1016/j.prmcm.2024.100457>
- Aregawi, L. G.**, Shokrolahi, M., Gebremeskel, T. G., Csiki, Z.: The Effect of Ginger Supplementation on the Improvement of Dyspeptic Symptoms in Patients With Functional Dyspepsia.
Cureus J. Med. Sci. 15 (9), 1-8, 2023.
DOI: <http://dx.doi.org/10.7759/cureus.46061>
IF: 1





6. Tukue, D., Gebremeskel, T. G., **Aregawi, L. G.**, Aregawi, B., Hagos, M. G., Gebremichael, T., Tesfay, H. N., Arefaine, Z. G.: Prevalence and determinants of modern contraceptive utilization among women in the reproductive age group in Edaga-hamus Town, Eastern zone, Tigray region, Ethiopia, June 2017.
PLoS One. 15 (3), 1-17, 2020.
DOI: <http://dx.doi.org/10.1371/journal.pone.0227795>
IF: 3.24
7. Teame, H., **Aregawi, L. G.**, Kahsay, T., Berhe, K., Gebreheat, G., Gebremariam, G.: Factors affecting utilization of cervical cancer screening services among women attending public hospitals in Tigray region, Ethiopia, 2018; Case control study.
PLoS One. 14 (3), 1-11, 2019.
DOI: <http://dx.doi.org/10.1371/journal.pone.0213546>
IF: 2.74

Total IF of journals (all publications): 9,78

Total IF of journals (publications related to the dissertation): 2,8

The Candidate's publication data submitted to the Tudóstér have been validated by DEENK on the basis of the Journal Citation Report (Impact Factor) database.

27 May, 2025

